StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 19 Sep 2025 07:24:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday SAB BIO Highlights Data in Multiple Presentations at EASD http://www.streetinsider.com/Press+Releases/SAB+BIO+Highlights+Data+in+Multiple+Presentations+at+EASD/25353500.html <p align="center"><em>-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in the study-</em></p> <p align="center"><em>-Data in multiple SAB presentations and INNODIA’s MELD-ATG study provide further validation for SAB-142 as a novel, potentially best-in-class, disease-modifying immunotherapeutic approach poised to redefine treatment of T1D- </em></p> <p>MIAMI, Sept. 19, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=t-7hR8Sbe-uz6ZhkF4YYNucl6WbqnQlpRFIg9iyK6_rRtb6UTj5-QNej20Ws50cT-1FWmxwEMd__zZzVaho9VupTCZoKnzVTuY4iTAQqCpwAdXVnSmsrAccw2DglgZGTvOSnJG-uNkVkt5nAvUB3KwUwid1XC0QjbMfDPWdQuQ6yBEazTv8k5y8KSUZaKQduYcazVWMiPkAnX20bphcUulQoxUlZMOL9FcqdOou0mDR0uMTOcnSuRXfvWyLLvZDsdPFJnPo1aw2SSsQE54Cw8dxE0ieuE2SjrCOxZEqyW-OyMZ2QaCuBoyhgFnduMEZkUIRvw69AsZp1epuSOzqmv3a6v1oZhi24Za0LxWBfzp-ugneGOWlelzoGgCo_WtgIqOW0K0bLcDIRQ6wmnmy0JhXK9o5EHuqTGOK9EG5F_gAv4PNQUqU3d9fGXnoNBjHs57LNB9Pw3TJuhI_cVY9cdGw-3NxHi0aj04RYfwCEBRZnlgZMUDm3XTZf87HBzsetyEAQj_u_IT2ZGYWrS_lTzmAEwMbR3YKrfYcN7IutU_5g6O-y4hxkbhwZyIhn86T8ARSrzB1AKPfrwqhG6OSDp6N3t2r1kgDSB4Q4AdzRcHv7fwlKhZeCEIN93bjNBdQl23aWHVuJCG3pVMGHpMqXES1WodohkTRKmiitbhj2cwKfsKoR8S2Xem7hgn6iBKt4zS8lSfZC8lD1gkNaoLykGa-Y5odYN2KjtwyU3gxw1yHbN_phZgj9qGAeuKy7Rn5MufzZP7-ImPNiz8lHX3-MlCFyVXfXztxZyMx4dtqWt-By5VGv3Na0fHrsqjrhU4BkKVuvrVOPlKl9tU9IIN6aCjD0HvX5QWUIUNM3taXoyNYJfrZD9Zv72KyYzUoShdD8Yst9Fxt4IBrvxvPeA-zWWCzDxvd6lRxzUuhxKLDXzoqYFm6ewJ5X_Wr-Mi7Y-1i9Log0dr0t5rcxfmxZ6lnsgfKSJK2LHp5S3HKO0rsfZDSSJQsdZdL8Fsqn-rBgRmT1i7duf3IPxiJMTt07ZcmOWYBqvsKFcnW--spFeZX57yAg3njScETCm7iFBK-onax38iSC4m_4kJEEe1ySMPK4RfOe4B4qSoVG6EZRJn0ulG-ZWdcKjpL53K76MfQVXYKW8JF_sQdOkuyMS_wcnesT0UfpFnxavk0vgjgbqbkmu91J83Gfdr1py4zpm4FTFeCvppqwOz-7KyPIAqjj8Lb1wNmcHvKumjDso92bt7Jl0iOlafcru1e9cZtupZz_zysYrTrmb-SzRkHrv4diUtbLnuT19nlt59Q7HYifoSRgGNOhZ1CjXZpBomAUwDq2h05iPf4rT1A9TBYOpofCou7dynAbHT-_pm02EHWMdqJsSB-Uv5zfyx7T7IbqJoyK8aceOiG7leVZOpLAblO3L2kGQc1t2_3M3ez5Za1Uf8SWYFHPa5ImpLlVjf-0F4ivuWCWNeysWgXbOZz_gS-9uOhZ3P9Gg-F62CnlLurmov4w_D-IpiHhJCmb758hIS2YmrO4AzvUXiJe96l0jJg6i8vfs89lj5O5rTArY7Ft75mLgGqQcISA9fgatfATHwXjCm5hDkdOv4Llq__-QlmhQLsCgZ_Sk3IOKWFAxi0yzagEKrg17qJBx2nmoR2b2DTbArbASJnn9Iay1hJMMcbpT0huSkGr_uNaJTb1UfXYzOXyh2h4EXeBNGe6RmZdBmkjIW4mT-GLxBPOrxHRVINoUU8dL_ZdRy1w5XdJvzIVqPg4pPYB94sEo_4FzaPaTQX9Fbw8i2qRYqE1Pbhef85fIAiZhdd7dMU9Zte8y1Gfh8NHY0S5OzCdoUEw9-yJ5ynSLnqZ0uy6s2Ovf-MtcRwuIBi8tLxLCVW2rAORzmFJ3O6rTZygCA-XAl69Sijbqb-ugNKdcTVanrxgWeNXQQYUx-S9-zZeu5uMo3PHqPsptKlybA2MGXcktLUonvmcEYhWZVD8Zh6NODQfo3ucRy7_4vTw6xula42ivTgmEYcIaMglbfknmyF5WYhtjNKK36xl8d_X6tQJvRM0ZyiTxPrc-FLAj2v-5N643zlqGNb4Ky30eO0Xyrm5GeKbsEk6I9HIXcSt" rel="nofollow" target="_blank">SABS</a>), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company that is developing human anti-thymocyte immunoglobulin (ATG) http://www.streetinsider.com/Press+Releases/SAB+BIO+Highlights+Data+in+Multiple+Presentations+at+EASD/25353500.html Fri, 19 Sep 2025 07:24:00 -0500 A.09642568 O.20371933 O.49911890 SABS SABSW SAB BIO Highlights Data in Multiple Presentations at EASD http://www.streetinsider.com/Press+Releases/SAB+BIO+Highlights+Data+in+Multiple+Presentations+at+EASD/25353500.html <p align="center"><em>-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in the study-</em></p> <p align="center"><em>-Data in multiple SAB presentations and INNODIA’s MELD-ATG study provide further validation for SAB-142 as a novel, potentially best-in-class, disease-modifying immunotherapeutic approach poised to redefine treatment of T1D- </em></p> <p>MIAMI, Sept. 19, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=t-7hR8Sbe-uz6ZhkF4YYNucl6WbqnQlpRFIg9iyK6_rRtb6UTj5-QNej20Ws50cT-1FWmxwEMd__zZzVaho9VupTCZoKnzVTuY4iTAQqCpwAdXVnSmsrAccw2DglgZGTvOSnJG-uNkVkt5nAvUB3KwUwid1XC0QjbMfDPWdQuQ6yBEazTv8k5y8KSUZaKQduYcazVWMiPkAnX20bphcUulQoxUlZMOL9FcqdOou0mDR0uMTOcnSuRXfvWyLLvZDsdPFJnPo1aw2SSsQE54Cw8dxE0ieuE2SjrCOxZEqyW-OyMZ2QaCuBoyhgFnduMEZkUIRvw69AsZp1epuSOzqmv3a6v1oZhi24Za0LxWBfzp-ugneGOWlelzoGgCo_WtgIqOW0K0bLcDIRQ6wmnmy0JhXK9o5EHuqTGOK9EG5F_gAv4PNQUqU3d9fGXnoNBjHs57LNB9Pw3TJuhI_cVY9cdGw-3NxHi0aj04RYfwCEBRZnlgZMUDm3XTZf87HBzsetyEAQj_u_IT2ZGYWrS_lTzmAEwMbR3YKrfYcN7IutU_5g6O-y4hxkbhwZyIhn86T8ARSrzB1AKPfrwqhG6OSDp6N3t2r1kgDSB4Q4AdzRcHv7fwlKhZeCEIN93bjNBdQl23aWHVuJCG3pVMGHpMqXES1WodohkTRKmiitbhj2cwKfsKoR8S2Xem7hgn6iBKt4zS8lSfZC8lD1gkNaoLykGa-Y5odYN2KjtwyU3gxw1yHbN_phZgj9qGAeuKy7Rn5MufzZP7-ImPNiz8lHX3-MlCFyVXfXztxZyMx4dtqWt-By5VGv3Na0fHrsqjrhU4BkKVuvrVOPlKl9tU9IIN6aCjD0HvX5QWUIUNM3taXoyNYJfrZD9Zv72KyYzUoShdD8Yst9Fxt4IBrvxvPeA-zWWCzDxvd6lRxzUuhxKLDXzoqYFm6ewJ5X_Wr-Mi7Y-1i9Log0dr0t5rcxfmxZ6lnsgfKSJK2LHp5S3HKO0rsfZDSSJQsdZdL8Fsqn-rBgRmT1i7duf3IPxiJMTt07ZcmOWYBqvsKFcnW--spFeZX57yAg3njScETCm7iFBK-onax38iSC4m_4kJEEe1ySMPK4RfOe4B4qSoVG6EZRJn0ulG-ZWdcKjpL53K76MfQVXYKW8JF_sQdOkuyMS_wcnesT0UfpFnxavk0vgjgbqbkmu91J83Gfdr1py4zpm4FTFeCvppqwOz-7KyPIAqjj8Lb1wNmcHvKumjDso92bt7Jl0iOlafcru1e9cZtupZz_zysYrTrmb-SzRkHrv4diUtbLnuT19nlt59Q7HYifoSRgGNOhZ1CjXZpBomAUwDq2h05iPf4rT1A9TBYOpofCou7dynAbHT-_pm02EHWMdqJsSB-Uv5zfyx7T7IbqJoyK8aceOiG7leVZOpLAblO3L2kGQc1t2_3M3ez5Za1Uf8SWYFHPa5ImpLlVjf-0F4ivuWCWNeysWgXbOZz_gS-9uOhZ3P9Gg-F62CnlLurmov4w_D-IpiHhJCmb758hIS2YmrO4AzvUXiJe96l0jJg6i8vfs89lj5O5rTArY7Ft75mLgGqQcISA9fgatfATHwXjCm5hDkdOv4Llq__-QlmhQLsCgZ_Sk3IOKWFAxi0yzagEKrg17qJBx2nmoR2b2DTbArbASJnn9Iay1hJMMcbpT0huSkGr_uNaJTb1UfXYzOXyh2h4EXeBNGe6RmZdBmkjIW4mT-GLxBPOrxHRVINoUU8dL_ZdRy1w5XdJvzIVqPg4pPYB94sEo_4FzaPaTQX9Fbw8i2qRYqE1Pbhef85fIAiZhdd7dMU9Zte8y1Gfh8NHY0S5OzCdoUEw9-yJ5ynSLnqZ0uy6s2Ovf-MtcRwuIBi8tLxLCVW2rAORzmFJ3O6rTZygCA-XAl69Sijbqb-ugNKdcTVanrxgWeNXQQYUx-S9-zZeu5uMo3PHqPsptKlybA2MGXcktLUonvmcEYhWZVD8Zh6NODQfo3ucRy7_4vTw6xula42ivTgmEYcIaMglbfknmyF5WYhtjNKK36xl8d_X6tQJvRM0ZyiTxPrc-FLAj2v-5N643zlqGNb4Ky30eO0Xyrm5GeKbsEk6I9HIXcSt" rel="nofollow" target="_blank">SABS</a>), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company that is developing human anti-thymocyte immunoglobulin (ATG) http://www.streetinsider.com/Press+Releases/SAB+BIO+Highlights+Data+in+Multiple+Presentations+at+EASD/25353500.html Fri, 19 Sep 2025 07:24:00 -0500 A.09642568 O.20371933 O.49911890 SABS SABSW SAB BIO Highlights Data in Multiple Presentations at EASD http://www.streetinsider.com/Press+Releases/SAB+BIO+Highlights+Data+in+Multiple+Presentations+at+EASD/25353500.html <p align="center"><em>-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in the study-</em></p> <p align="center"><em>-Data in multiple SAB presentations and INNODIA’s MELD-ATG study provide further validation for SAB-142 as a novel, potentially best-in-class, disease-modifying immunotherapeutic approach poised to redefine treatment of T1D- </em></p> <p>MIAMI, Sept. 19, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=t-7hR8Sbe-uz6ZhkF4YYNucl6WbqnQlpRFIg9iyK6_rRtb6UTj5-QNej20Ws50cT-1FWmxwEMd__zZzVaho9VupTCZoKnzVTuY4iTAQqCpwAdXVnSmsrAccw2DglgZGTvOSnJG-uNkVkt5nAvUB3KwUwid1XC0QjbMfDPWdQuQ6yBEazTv8k5y8KSUZaKQduYcazVWMiPkAnX20bphcUulQoxUlZMOL9FcqdOou0mDR0uMTOcnSuRXfvWyLLvZDsdPFJnPo1aw2SSsQE54Cw8dxE0ieuE2SjrCOxZEqyW-OyMZ2QaCuBoyhgFnduMEZkUIRvw69AsZp1epuSOzqmv3a6v1oZhi24Za0LxWBfzp-ugneGOWlelzoGgCo_WtgIqOW0K0bLcDIRQ6wmnmy0JhXK9o5EHuqTGOK9EG5F_gAv4PNQUqU3d9fGXnoNBjHs57LNB9Pw3TJuhI_cVY9cdGw-3NxHi0aj04RYfwCEBRZnlgZMUDm3XTZf87HBzsetyEAQj_u_IT2ZGYWrS_lTzmAEwMbR3YKrfYcN7IutU_5g6O-y4hxkbhwZyIhn86T8ARSrzB1AKPfrwqhG6OSDp6N3t2r1kgDSB4Q4AdzRcHv7fwlKhZeCEIN93bjNBdQl23aWHVuJCG3pVMGHpMqXES1WodohkTRKmiitbhj2cwKfsKoR8S2Xem7hgn6iBKt4zS8lSfZC8lD1gkNaoLykGa-Y5odYN2KjtwyU3gxw1yHbN_phZgj9qGAeuKy7Rn5MufzZP7-ImPNiz8lHX3-MlCFyVXfXztxZyMx4dtqWt-By5VGv3Na0fHrsqjrhU4BkKVuvrVOPlKl9tU9IIN6aCjD0HvX5QWUIUNM3taXoyNYJfrZD9Zv72KyYzUoShdD8Yst9Fxt4IBrvxvPeA-zWWCzDxvd6lRxzUuhxKLDXzoqYFm6ewJ5X_Wr-Mi7Y-1i9Log0dr0t5rcxfmxZ6lnsgfKSJK2LHp5S3HKO0rsfZDSSJQsdZdL8Fsqn-rBgRmT1i7duf3IPxiJMTt07ZcmOWYBqvsKFcnW--spFeZX57yAg3njScETCm7iFBK-onax38iSC4m_4kJEEe1ySMPK4RfOe4B4qSoVG6EZRJn0ulG-ZWdcKjpL53K76MfQVXYKW8JF_sQdOkuyMS_wcnesT0UfpFnxavk0vgjgbqbkmu91J83Gfdr1py4zpm4FTFeCvppqwOz-7KyPIAqjj8Lb1wNmcHvKumjDso92bt7Jl0iOlafcru1e9cZtupZz_zysYrTrmb-SzRkHrv4diUtbLnuT19nlt59Q7HYifoSRgGNOhZ1CjXZpBomAUwDq2h05iPf4rT1A9TBYOpofCou7dynAbHT-_pm02EHWMdqJsSB-Uv5zfyx7T7IbqJoyK8aceOiG7leVZOpLAblO3L2kGQc1t2_3M3ez5Za1Uf8SWYFHPa5ImpLlVjf-0F4ivuWCWNeysWgXbOZz_gS-9uOhZ3P9Gg-F62CnlLurmov4w_D-IpiHhJCmb758hIS2YmrO4AzvUXiJe96l0jJg6i8vfs89lj5O5rTArY7Ft75mLgGqQcISA9fgatfATHwXjCm5hDkdOv4Llq__-QlmhQLsCgZ_Sk3IOKWFAxi0yzagEKrg17qJBx2nmoR2b2DTbArbASJnn9Iay1hJMMcbpT0huSkGr_uNaJTb1UfXYzOXyh2h4EXeBNGe6RmZdBmkjIW4mT-GLxBPOrxHRVINoUU8dL_ZdRy1w5XdJvzIVqPg4pPYB94sEo_4FzaPaTQX9Fbw8i2qRYqE1Pbhef85fIAiZhdd7dMU9Zte8y1Gfh8NHY0S5OzCdoUEw9-yJ5ynSLnqZ0uy6s2Ovf-MtcRwuIBi8tLxLCVW2rAORzmFJ3O6rTZygCA-XAl69Sijbqb-ugNKdcTVanrxgWeNXQQYUx-S9-zZeu5uMo3PHqPsptKlybA2MGXcktLUonvmcEYhWZVD8Zh6NODQfo3ucRy7_4vTw6xula42ivTgmEYcIaMglbfknmyF5WYhtjNKK36xl8d_X6tQJvRM0ZyiTxPrc-FLAj2v-5N643zlqGNb4Ky30eO0Xyrm5GeKbsEk6I9HIXcSt" rel="nofollow" target="_blank">SABS</a>), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company that is developing human anti-thymocyte immunoglobulin (ATG) http://www.streetinsider.com/Press+Releases/SAB+BIO+Highlights+Data+in+Multiple+Presentations+at+EASD/25353500.html Fri, 19 Sep 2025 07:24:00 -0500 A.09642568 O.20371933 O.49911890 SABS SABSW SAB BIO Highlights Data in Multiple Presentations at EASD http://www.streetinsider.com/Press+Releases/SAB+BIO+Highlights+Data+in+Multiple+Presentations+at+EASD/25353500.html <p align="center"><em>-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in the study-</em></p> <p align="center"><em>-Data in multiple SAB presentations and INNODIA’s MELD-ATG study provide further validation for SAB-142 as a novel, potentially best-in-class, disease-modifying immunotherapeutic approach poised to redefine treatment of T1D- </em></p> <p>MIAMI, Sept. 19, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=t-7hR8Sbe-uz6ZhkF4YYNucl6WbqnQlpRFIg9iyK6_rRtb6UTj5-QNej20Ws50cT-1FWmxwEMd__zZzVaho9VupTCZoKnzVTuY4iTAQqCpwAdXVnSmsrAccw2DglgZGTvOSnJG-uNkVkt5nAvUB3KwUwid1XC0QjbMfDPWdQuQ6yBEazTv8k5y8KSUZaKQduYcazVWMiPkAnX20bphcUulQoxUlZMOL9FcqdOou0mDR0uMTOcnSuRXfvWyLLvZDsdPFJnPo1aw2SSsQE54Cw8dxE0ieuE2SjrCOxZEqyW-OyMZ2QaCuBoyhgFnduMEZkUIRvw69AsZp1epuSOzqmv3a6v1oZhi24Za0LxWBfzp-ugneGOWlelzoGgCo_WtgIqOW0K0bLcDIRQ6wmnmy0JhXK9o5EHuqTGOK9EG5F_gAv4PNQUqU3d9fGXnoNBjHs57LNB9Pw3TJuhI_cVY9cdGw-3NxHi0aj04RYfwCEBRZnlgZMUDm3XTZf87HBzsetyEAQj_u_IT2ZGYWrS_lTzmAEwMbR3YKrfYcN7IutU_5g6O-y4hxkbhwZyIhn86T8ARSrzB1AKPfrwqhG6OSDp6N3t2r1kgDSB4Q4AdzRcHv7fwlKhZeCEIN93bjNBdQl23aWHVuJCG3pVMGHpMqXES1WodohkTRKmiitbhj2cwKfsKoR8S2Xem7hgn6iBKt4zS8lSfZC8lD1gkNaoLykGa-Y5odYN2KjtwyU3gxw1yHbN_phZgj9qGAeuKy7Rn5MufzZP7-ImPNiz8lHX3-MlCFyVXfXztxZyMx4dtqWt-By5VGv3Na0fHrsqjrhU4BkKVuvrVOPlKl9tU9IIN6aCjD0HvX5QWUIUNM3taXoyNYJfrZD9Zv72KyYzUoShdD8Yst9Fxt4IBrvxvPeA-zWWCzDxvd6lRxzUuhxKLDXzoqYFm6ewJ5X_Wr-Mi7Y-1i9Log0dr0t5rcxfmxZ6lnsgfKSJK2LHp5S3HKO0rsfZDSSJQsdZdL8Fsqn-rBgRmT1i7duf3IPxiJMTt07ZcmOWYBqvsKFcnW--spFeZX57yAg3njScETCm7iFBK-onax38iSC4m_4kJEEe1ySMPK4RfOe4B4qSoVG6EZRJn0ulG-ZWdcKjpL53K76MfQVXYKW8JF_sQdOkuyMS_wcnesT0UfpFnxavk0vgjgbqbkmu91J83Gfdr1py4zpm4FTFeCvppqwOz-7KyPIAqjj8Lb1wNmcHvKumjDso92bt7Jl0iOlafcru1e9cZtupZz_zysYrTrmb-SzRkHrv4diUtbLnuT19nlt59Q7HYifoSRgGNOhZ1CjXZpBomAUwDq2h05iPf4rT1A9TBYOpofCou7dynAbHT-_pm02EHWMdqJsSB-Uv5zfyx7T7IbqJoyK8aceOiG7leVZOpLAblO3L2kGQc1t2_3M3ez5Za1Uf8SWYFHPa5ImpLlVjf-0F4ivuWCWNeysWgXbOZz_gS-9uOhZ3P9Gg-F62CnlLurmov4w_D-IpiHhJCmb758hIS2YmrO4AzvUXiJe96l0jJg6i8vfs89lj5O5rTArY7Ft75mLgGqQcISA9fgatfATHwXjCm5hDkdOv4Llq__-QlmhQLsCgZ_Sk3IOKWFAxi0yzagEKrg17qJBx2nmoR2b2DTbArbASJnn9Iay1hJMMcbpT0huSkGr_uNaJTb1UfXYzOXyh2h4EXeBNGe6RmZdBmkjIW4mT-GLxBPOrxHRVINoUU8dL_ZdRy1w5XdJvzIVqPg4pPYB94sEo_4FzaPaTQX9Fbw8i2qRYqE1Pbhef85fIAiZhdd7dMU9Zte8y1Gfh8NHY0S5OzCdoUEw9-yJ5ynSLnqZ0uy6s2Ovf-MtcRwuIBi8tLxLCVW2rAORzmFJ3O6rTZygCA-XAl69Sijbqb-ugNKdcTVanrxgWeNXQQYUx-S9-zZeu5uMo3PHqPsptKlybA2MGXcktLUonvmcEYhWZVD8Zh6NODQfo3ucRy7_4vTw6xula42ivTgmEYcIaMglbfknmyF5WYhtjNKK36xl8d_X6tQJvRM0ZyiTxPrc-FLAj2v-5N643zlqGNb4Ky30eO0Xyrm5GeKbsEk6I9HIXcSt" rel="nofollow" target="_blank">SABS</a>), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company that is developing human anti-thymocyte immunoglobulin (ATG) http://www.streetinsider.com/Press+Releases/SAB+BIO+Highlights+Data+in+Multiple+Presentations+at+EASD/25353500.html Fri, 19 Sep 2025 07:24:00 -0500 A.09642568 O.20371933 O.49911890 SABS SABSW SAB BIO Highlights Data in Multiple Presentations at EASD http://www.streetinsider.com/Press+Releases/SAB+BIO+Highlights+Data+in+Multiple+Presentations+at+EASD/25353500.html <p align="center"><em>-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in the study-</em></p> <p align="center"><em>-Data in multiple SAB presentations and INNODIA’s MELD-ATG study provide further validation for SAB-142 as a novel, potentially best-in-class, disease-modifying immunotherapeutic approach poised to redefine treatment of T1D- </em></p> <p>MIAMI, Sept. 19, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=t-7hR8Sbe-uz6ZhkF4YYNucl6WbqnQlpRFIg9iyK6_rRtb6UTj5-QNej20Ws50cT-1FWmxwEMd__zZzVaho9VupTCZoKnzVTuY4iTAQqCpwAdXVnSmsrAccw2DglgZGTvOSnJG-uNkVkt5nAvUB3KwUwid1XC0QjbMfDPWdQuQ6yBEazTv8k5y8KSUZaKQduYcazVWMiPkAnX20bphcUulQoxUlZMOL9FcqdOou0mDR0uMTOcnSuRXfvWyLLvZDsdPFJnPo1aw2SSsQE54Cw8dxE0ieuE2SjrCOxZEqyW-OyMZ2QaCuBoyhgFnduMEZkUIRvw69AsZp1epuSOzqmv3a6v1oZhi24Za0LxWBfzp-ugneGOWlelzoGgCo_WtgIqOW0K0bLcDIRQ6wmnmy0JhXK9o5EHuqTGOK9EG5F_gAv4PNQUqU3d9fGXnoNBjHs57LNB9Pw3TJuhI_cVY9cdGw-3NxHi0aj04RYfwCEBRZnlgZMUDm3XTZf87HBzsetyEAQj_u_IT2ZGYWrS_lTzmAEwMbR3YKrfYcN7IutU_5g6O-y4hxkbhwZyIhn86T8ARSrzB1AKPfrwqhG6OSDp6N3t2r1kgDSB4Q4AdzRcHv7fwlKhZeCEIN93bjNBdQl23aWHVuJCG3pVMGHpMqXES1WodohkTRKmiitbhj2cwKfsKoR8S2Xem7hgn6iBKt4zS8lSfZC8lD1gkNaoLykGa-Y5odYN2KjtwyU3gxw1yHbN_phZgj9qGAeuKy7Rn5MufzZP7-ImPNiz8lHX3-MlCFyVXfXztxZyMx4dtqWt-By5VGv3Na0fHrsqjrhU4BkKVuvrVOPlKl9tU9IIN6aCjD0HvX5QWUIUNM3taXoyNYJfrZD9Zv72KyYzUoShdD8Yst9Fxt4IBrvxvPeA-zWWCzDxvd6lRxzUuhxKLDXzoqYFm6ewJ5X_Wr-Mi7Y-1i9Log0dr0t5rcxfmxZ6lnsgfKSJK2LHp5S3HKO0rsfZDSSJQsdZdL8Fsqn-rBgRmT1i7duf3IPxiJMTt07ZcmOWYBqvsKFcnW--spFeZX57yAg3njScETCm7iFBK-onax38iSC4m_4kJEEe1ySMPK4RfOe4B4qSoVG6EZRJn0ulG-ZWdcKjpL53K76MfQVXYKW8JF_sQdOkuyMS_wcnesT0UfpFnxavk0vgjgbqbkmu91J83Gfdr1py4zpm4FTFeCvppqwOz-7KyPIAqjj8Lb1wNmcHvKumjDso92bt7Jl0iOlafcru1e9cZtupZz_zysYrTrmb-SzRkHrv4diUtbLnuT19nlt59Q7HYifoSRgGNOhZ1CjXZpBomAUwDq2h05iPf4rT1A9TBYOpofCou7dynAbHT-_pm02EHWMdqJsSB-Uv5zfyx7T7IbqJoyK8aceOiG7leVZOpLAblO3L2kGQc1t2_3M3ez5Za1Uf8SWYFHPa5ImpLlVjf-0F4ivuWCWNeysWgXbOZz_gS-9uOhZ3P9Gg-F62CnlLurmov4w_D-IpiHhJCmb758hIS2YmrO4AzvUXiJe96l0jJg6i8vfs89lj5O5rTArY7Ft75mLgGqQcISA9fgatfATHwXjCm5hDkdOv4Llq__-QlmhQLsCgZ_Sk3IOKWFAxi0yzagEKrg17qJBx2nmoR2b2DTbArbASJnn9Iay1hJMMcbpT0huSkGr_uNaJTb1UfXYzOXyh2h4EXeBNGe6RmZdBmkjIW4mT-GLxBPOrxHRVINoUU8dL_ZdRy1w5XdJvzIVqPg4pPYB94sEo_4FzaPaTQX9Fbw8i2qRYqE1Pbhef85fIAiZhdd7dMU9Zte8y1Gfh8NHY0S5OzCdoUEw9-yJ5ynSLnqZ0uy6s2Ovf-MtcRwuIBi8tLxLCVW2rAORzmFJ3O6rTZygCA-XAl69Sijbqb-ugNKdcTVanrxgWeNXQQYUx-S9-zZeu5uMo3PHqPsptKlybA2MGXcktLUonvmcEYhWZVD8Zh6NODQfo3ucRy7_4vTw6xula42ivTgmEYcIaMglbfknmyF5WYhtjNKK36xl8d_X6tQJvRM0ZyiTxPrc-FLAj2v-5N643zlqGNb4Ky30eO0Xyrm5GeKbsEk6I9HIXcSt" rel="nofollow" target="_blank">SABS</a>), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company that is developing human anti-thymocyte immunoglobulin (ATG) http://www.streetinsider.com/Press+Releases/SAB+BIO+Highlights+Data+in+Multiple+Presentations+at+EASD/25353500.html Fri, 19 Sep 2025 07:24:00 -0500 A.09642568 O.20371933 O.49911890 SABS SABSW SAB BIO Highlights Data in Multiple Presentations at EASD http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Highlights+Data+in+Multiple+Presentations+at+EASD/25353500.html <p align="center"><em>-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in the study-</em></p> <p align="center"><em>-Data in multiple SAB presentations and INNODIA’s MELD-ATG study provide further validation for SAB-142 as a novel, potentially best-in-class, disease-modifying immunotherapeutic approach poised to redefine treatment of T1D- </em></p> <p>MIAMI, Sept. 19, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=t-7hR8Sbe-uz6ZhkF4YYNucl6WbqnQlpRFIg9iyK6_rRtb6UTj5-QNej20Ws50cT-1FWmxwEMd__zZzVaho9VupTCZoKnzVTuY4iTAQqCpwAdXVnSmsrAccw2DglgZGTvOSnJG-uNkVkt5nAvUB3KwUwid1XC0QjbMfDPWdQuQ6yBEazTv8k5y8KSUZaKQduYcazVWMiPkAnX20bphcUulQoxUlZMOL9FcqdOou0mDR0uMTOcnSuRXfvWyLLvZDsdPFJnPo1aw2SSsQE54Cw8dxE0ieuE2SjrCOxZEqyW-OyMZ2QaCuBoyhgFnduMEZkUIRvw69AsZp1epuSOzqmv3a6v1oZhi24Za0LxWBfzp-ugneGOWlelzoGgCo_WtgIqOW0K0bLcDIRQ6wmnmy0JhXK9o5EHuqTGOK9EG5F_gAv4PNQUqU3d9fGXnoNBjHs57LNB9Pw3TJuhI_cVY9cdGw-3NxHi0aj04RYfwCEBRZnlgZMUDm3XTZf87HBzsetyEAQj_u_IT2ZGYWrS_lTzmAEwMbR3YKrfYcN7IutU_5g6O-y4hxkbhwZyIhn86T8ARSrzB1AKPfrwqhG6OSDp6N3t2r1kgDSB4Q4AdzRcHv7fwlKhZeCEIN93bjNBdQl23aWHVuJCG3pVMGHpMqXES1WodohkTRKmiitbhj2cwKfsKoR8S2Xem7hgn6iBKt4zS8lSfZC8lD1gkNaoLykGa-Y5odYN2KjtwyU3gxw1yHbN_phZgj9qGAeuKy7Rn5MufzZP7-ImPNiz8lHX3-MlCFyVXfXztxZyMx4dtqWt-By5VGv3Na0fHrsqjrhU4BkKVuvrVOPlKl9tU9IIN6aCjD0HvX5QWUIUNM3taXoyNYJfrZD9Zv72KyYzUoShdD8Yst9Fxt4IBrvxvPeA-zWWCzDxvd6lRxzUuhxKLDXzoqYFm6ewJ5X_Wr-Mi7Y-1i9Log0dr0t5rcxfmxZ6lnsgfKSJK2LHp5S3HKO0rsfZDSSJQsdZdL8Fsqn-rBgRmT1i7duf3IPxiJMTt07ZcmOWYBqvsKFcnW--spFeZX57yAg3njScETCm7iFBK-onax38iSC4m_4kJEEe1ySMPK4RfOe4B4qSoVG6EZRJn0ulG-ZWdcKjpL53K76MfQVXYKW8JF_sQdOkuyMS_wcnesT0UfpFnxavk0vgjgbqbkmu91J83Gfdr1py4zpm4FTFeCvppqwOz-7KyPIAqjj8Lb1wNmcHvKumjDso92bt7Jl0iOlafcru1e9cZtupZz_zysYrTrmb-SzRkHrv4diUtbLnuT19nlt59Q7HYifoSRgGNOhZ1CjXZpBomAUwDq2h05iPf4rT1A9TBYOpofCou7dynAbHT-_pm02EHWMdqJsSB-Uv5zfyx7T7IbqJoyK8aceOiG7leVZOpLAblO3L2kGQc1t2_3M3ez5Za1Uf8SWYFHPa5ImpLlVjf-0F4ivuWCWNeysWgXbOZz_gS-9uOhZ3P9Gg-F62CnlLurmov4w_D-IpiHhJCmb758hIS2YmrO4AzvUXiJe96l0jJg6i8vfs89lj5O5rTArY7Ft75mLgGqQcISA9fgatfATHwXjCm5hDkdOv4Llq__-QlmhQLsCgZ_Sk3IOKWFAxi0yzagEKrg17qJBx2nmoR2b2DTbArbASJnn9Iay1hJMMcbpT0huSkGr_uNaJTb1UfXYzOXyh2h4EXeBNGe6RmZdBmkjIW4mT-GLxBPOrxHRVINoUU8dL_ZdRy1w5XdJvzIVqPg4pPYB94sEo_4FzaPaTQX9Fbw8i2qRYqE1Pbhef85fIAiZhdd7dMU9Zte8y1Gfh8NHY0S5OzCdoUEw9-yJ5ynSLnqZ0uy6s2Ovf-MtcRwuIBi8tLxLCVW2rAORzmFJ3O6rTZygCA-XAl69Sijbqb-ugNKdcTVanrxgWeNXQQYUx-S9-zZeu5uMo3PHqPsptKlybA2MGXcktLUonvmcEYhWZVD8Zh6NODQfo3ucRy7_4vTw6xula42ivTgmEYcIaMglbfknmyF5WYhtjNKK36xl8d_X6tQJvRM0ZyiTxPrc-FLAj2v-5N643zlqGNb4Ky30eO0Xyrm5GeKbsEk6I9HIXcSt" rel="nofollow" target="_blank">SABS</a>), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company that is developing human anti-thymocyte immunoglobulin (ATG) http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Highlights+Data+in+Multiple+Presentations+at+EASD/25353500.html Fri, 19 Sep 2025 07:24:00 -0500 A.09642568 O.20371933 O.49911890 SABS SABSW SAB BIO Highlights Data in Multiple Presentations at EASD http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Highlights+Data+in+Multiple+Presentations+at+EASD/25353500.html <p align="center"><em>-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in the study-</em></p> <p align="center"><em>-Data in multiple SAB presentations and INNODIA’s MELD-ATG study provide further validation for SAB-142 as a novel, potentially best-in-class, disease-modifying immunotherapeutic approach poised to redefine treatment of T1D- </em></p> <p>MIAMI, Sept. 19, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=t-7hR8Sbe-uz6ZhkF4YYNucl6WbqnQlpRFIg9iyK6_rRtb6UTj5-QNej20Ws50cT-1FWmxwEMd__zZzVaho9VupTCZoKnzVTuY4iTAQqCpwAdXVnSmsrAccw2DglgZGTvOSnJG-uNkVkt5nAvUB3KwUwid1XC0QjbMfDPWdQuQ6yBEazTv8k5y8KSUZaKQduYcazVWMiPkAnX20bphcUulQoxUlZMOL9FcqdOou0mDR0uMTOcnSuRXfvWyLLvZDsdPFJnPo1aw2SSsQE54Cw8dxE0ieuE2SjrCOxZEqyW-OyMZ2QaCuBoyhgFnduMEZkUIRvw69AsZp1epuSOzqmv3a6v1oZhi24Za0LxWBfzp-ugneGOWlelzoGgCo_WtgIqOW0K0bLcDIRQ6wmnmy0JhXK9o5EHuqTGOK9EG5F_gAv4PNQUqU3d9fGXnoNBjHs57LNB9Pw3TJuhI_cVY9cdGw-3NxHi0aj04RYfwCEBRZnlgZMUDm3XTZf87HBzsetyEAQj_u_IT2ZGYWrS_lTzmAEwMbR3YKrfYcN7IutU_5g6O-y4hxkbhwZyIhn86T8ARSrzB1AKPfrwqhG6OSDp6N3t2r1kgDSB4Q4AdzRcHv7fwlKhZeCEIN93bjNBdQl23aWHVuJCG3pVMGHpMqXES1WodohkTRKmiitbhj2cwKfsKoR8S2Xem7hgn6iBKt4zS8lSfZC8lD1gkNaoLykGa-Y5odYN2KjtwyU3gxw1yHbN_phZgj9qGAeuKy7Rn5MufzZP7-ImPNiz8lHX3-MlCFyVXfXztxZyMx4dtqWt-By5VGv3Na0fHrsqjrhU4BkKVuvrVOPlKl9tU9IIN6aCjD0HvX5QWUIUNM3taXoyNYJfrZD9Zv72KyYzUoShdD8Yst9Fxt4IBrvxvPeA-zWWCzDxvd6lRxzUuhxKLDXzoqYFm6ewJ5X_Wr-Mi7Y-1i9Log0dr0t5rcxfmxZ6lnsgfKSJK2LHp5S3HKO0rsfZDSSJQsdZdL8Fsqn-rBgRmT1i7duf3IPxiJMTt07ZcmOWYBqvsKFcnW--spFeZX57yAg3njScETCm7iFBK-onax38iSC4m_4kJEEe1ySMPK4RfOe4B4qSoVG6EZRJn0ulG-ZWdcKjpL53K76MfQVXYKW8JF_sQdOkuyMS_wcnesT0UfpFnxavk0vgjgbqbkmu91J83Gfdr1py4zpm4FTFeCvppqwOz-7KyPIAqjj8Lb1wNmcHvKumjDso92bt7Jl0iOlafcru1e9cZtupZz_zysYrTrmb-SzRkHrv4diUtbLnuT19nlt59Q7HYifoSRgGNOhZ1CjXZpBomAUwDq2h05iPf4rT1A9TBYOpofCou7dynAbHT-_pm02EHWMdqJsSB-Uv5zfyx7T7IbqJoyK8aceOiG7leVZOpLAblO3L2kGQc1t2_3M3ez5Za1Uf8SWYFHPa5ImpLlVjf-0F4ivuWCWNeysWgXbOZz_gS-9uOhZ3P9Gg-F62CnlLurmov4w_D-IpiHhJCmb758hIS2YmrO4AzvUXiJe96l0jJg6i8vfs89lj5O5rTArY7Ft75mLgGqQcISA9fgatfATHwXjCm5hDkdOv4Llq__-QlmhQLsCgZ_Sk3IOKWFAxi0yzagEKrg17qJBx2nmoR2b2DTbArbASJnn9Iay1hJMMcbpT0huSkGr_uNaJTb1UfXYzOXyh2h4EXeBNGe6RmZdBmkjIW4mT-GLxBPOrxHRVINoUU8dL_ZdRy1w5XdJvzIVqPg4pPYB94sEo_4FzaPaTQX9Fbw8i2qRYqE1Pbhef85fIAiZhdd7dMU9Zte8y1Gfh8NHY0S5OzCdoUEw9-yJ5ynSLnqZ0uy6s2Ovf-MtcRwuIBi8tLxLCVW2rAORzmFJ3O6rTZygCA-XAl69Sijbqb-ugNKdcTVanrxgWeNXQQYUx-S9-zZeu5uMo3PHqPsptKlybA2MGXcktLUonvmcEYhWZVD8Zh6NODQfo3ucRy7_4vTw6xula42ivTgmEYcIaMglbfknmyF5WYhtjNKK36xl8d_X6tQJvRM0ZyiTxPrc-FLAj2v-5N643zlqGNb4Ky30eO0Xyrm5GeKbsEk6I9HIXcSt" rel="nofollow" target="_blank">SABS</a>), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company that is developing human anti-thymocyte immunoglobulin (ATG) http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Highlights+Data+in+Multiple+Presentations+at+EASD/25353500.html Fri, 19 Sep 2025 07:24:00 -0500 A.09642568 O.20371933 O.49911890 SABS SABSW SAB BIO Highlights Data in Multiple Presentations at EASD http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Highlights+Data+in+Multiple+Presentations+at+EASD/25353500.html <p align="center"><em>-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in the study-</em></p> <p align="center"><em>-Data in multiple SAB presentations and INNODIA’s MELD-ATG study provide further validation for SAB-142 as a novel, potentially best-in-class, disease-modifying immunotherapeutic approach poised to redefine treatment of T1D- </em></p> <p>MIAMI, Sept. 19, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=t-7hR8Sbe-uz6ZhkF4YYNucl6WbqnQlpRFIg9iyK6_rRtb6UTj5-QNej20Ws50cT-1FWmxwEMd__zZzVaho9VupTCZoKnzVTuY4iTAQqCpwAdXVnSmsrAccw2DglgZGTvOSnJG-uNkVkt5nAvUB3KwUwid1XC0QjbMfDPWdQuQ6yBEazTv8k5y8KSUZaKQduYcazVWMiPkAnX20bphcUulQoxUlZMOL9FcqdOou0mDR0uMTOcnSuRXfvWyLLvZDsdPFJnPo1aw2SSsQE54Cw8dxE0ieuE2SjrCOxZEqyW-OyMZ2QaCuBoyhgFnduMEZkUIRvw69AsZp1epuSOzqmv3a6v1oZhi24Za0LxWBfzp-ugneGOWlelzoGgCo_WtgIqOW0K0bLcDIRQ6wmnmy0JhXK9o5EHuqTGOK9EG5F_gAv4PNQUqU3d9fGXnoNBjHs57LNB9Pw3TJuhI_cVY9cdGw-3NxHi0aj04RYfwCEBRZnlgZMUDm3XTZf87HBzsetyEAQj_u_IT2ZGYWrS_lTzmAEwMbR3YKrfYcN7IutU_5g6O-y4hxkbhwZyIhn86T8ARSrzB1AKPfrwqhG6OSDp6N3t2r1kgDSB4Q4AdzRcHv7fwlKhZeCEIN93bjNBdQl23aWHVuJCG3pVMGHpMqXES1WodohkTRKmiitbhj2cwKfsKoR8S2Xem7hgn6iBKt4zS8lSfZC8lD1gkNaoLykGa-Y5odYN2KjtwyU3gxw1yHbN_phZgj9qGAeuKy7Rn5MufzZP7-ImPNiz8lHX3-MlCFyVXfXztxZyMx4dtqWt-By5VGv3Na0fHrsqjrhU4BkKVuvrVOPlKl9tU9IIN6aCjD0HvX5QWUIUNM3taXoyNYJfrZD9Zv72KyYzUoShdD8Yst9Fxt4IBrvxvPeA-zWWCzDxvd6lRxzUuhxKLDXzoqYFm6ewJ5X_Wr-Mi7Y-1i9Log0dr0t5rcxfmxZ6lnsgfKSJK2LHp5S3HKO0rsfZDSSJQsdZdL8Fsqn-rBgRmT1i7duf3IPxiJMTt07ZcmOWYBqvsKFcnW--spFeZX57yAg3njScETCm7iFBK-onax38iSC4m_4kJEEe1ySMPK4RfOe4B4qSoVG6EZRJn0ulG-ZWdcKjpL53K76MfQVXYKW8JF_sQdOkuyMS_wcnesT0UfpFnxavk0vgjgbqbkmu91J83Gfdr1py4zpm4FTFeCvppqwOz-7KyPIAqjj8Lb1wNmcHvKumjDso92bt7Jl0iOlafcru1e9cZtupZz_zysYrTrmb-SzRkHrv4diUtbLnuT19nlt59Q7HYifoSRgGNOhZ1CjXZpBomAUwDq2h05iPf4rT1A9TBYOpofCou7dynAbHT-_pm02EHWMdqJsSB-Uv5zfyx7T7IbqJoyK8aceOiG7leVZOpLAblO3L2kGQc1t2_3M3ez5Za1Uf8SWYFHPa5ImpLlVjf-0F4ivuWCWNeysWgXbOZz_gS-9uOhZ3P9Gg-F62CnlLurmov4w_D-IpiHhJCmb758hIS2YmrO4AzvUXiJe96l0jJg6i8vfs89lj5O5rTArY7Ft75mLgGqQcISA9fgatfATHwXjCm5hDkdOv4Llq__-QlmhQLsCgZ_Sk3IOKWFAxi0yzagEKrg17qJBx2nmoR2b2DTbArbASJnn9Iay1hJMMcbpT0huSkGr_uNaJTb1UfXYzOXyh2h4EXeBNGe6RmZdBmkjIW4mT-GLxBPOrxHRVINoUU8dL_ZdRy1w5XdJvzIVqPg4pPYB94sEo_4FzaPaTQX9Fbw8i2qRYqE1Pbhef85fIAiZhdd7dMU9Zte8y1Gfh8NHY0S5OzCdoUEw9-yJ5ynSLnqZ0uy6s2Ovf-MtcRwuIBi8tLxLCVW2rAORzmFJ3O6rTZygCA-XAl69Sijbqb-ugNKdcTVanrxgWeNXQQYUx-S9-zZeu5uMo3PHqPsptKlybA2MGXcktLUonvmcEYhWZVD8Zh6NODQfo3ucRy7_4vTw6xula42ivTgmEYcIaMglbfknmyF5WYhtjNKK36xl8d_X6tQJvRM0ZyiTxPrc-FLAj2v-5N643zlqGNb4Ky30eO0Xyrm5GeKbsEk6I9HIXcSt" rel="nofollow" target="_blank">SABS</a>), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company that is developing human anti-thymocyte immunoglobulin (ATG) http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Highlights+Data+in+Multiple+Presentations+at+EASD/25353500.html Fri, 19 Sep 2025 07:24:00 -0500 A.09642568 O.20371933 O.49911890 SABS SABSW SAB BIO Highlights Data in Multiple Presentations at EASD http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Highlights+Data+in+Multiple+Presentations+at+EASD/25353500.html <p align="center"><em>-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in the study-</em></p> <p align="center"><em>-Data in multiple SAB presentations and INNODIA’s MELD-ATG study provide further validation for SAB-142 as a novel, potentially best-in-class, disease-modifying immunotherapeutic approach poised to redefine treatment of T1D- </em></p> <p>MIAMI, Sept. 19, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=t-7hR8Sbe-uz6ZhkF4YYNucl6WbqnQlpRFIg9iyK6_rRtb6UTj5-QNej20Ws50cT-1FWmxwEMd__zZzVaho9VupTCZoKnzVTuY4iTAQqCpwAdXVnSmsrAccw2DglgZGTvOSnJG-uNkVkt5nAvUB3KwUwid1XC0QjbMfDPWdQuQ6yBEazTv8k5y8KSUZaKQduYcazVWMiPkAnX20bphcUulQoxUlZMOL9FcqdOou0mDR0uMTOcnSuRXfvWyLLvZDsdPFJnPo1aw2SSsQE54Cw8dxE0ieuE2SjrCOxZEqyW-OyMZ2QaCuBoyhgFnduMEZkUIRvw69AsZp1epuSOzqmv3a6v1oZhi24Za0LxWBfzp-ugneGOWlelzoGgCo_WtgIqOW0K0bLcDIRQ6wmnmy0JhXK9o5EHuqTGOK9EG5F_gAv4PNQUqU3d9fGXnoNBjHs57LNB9Pw3TJuhI_cVY9cdGw-3NxHi0aj04RYfwCEBRZnlgZMUDm3XTZf87HBzsetyEAQj_u_IT2ZGYWrS_lTzmAEwMbR3YKrfYcN7IutU_5g6O-y4hxkbhwZyIhn86T8ARSrzB1AKPfrwqhG6OSDp6N3t2r1kgDSB4Q4AdzRcHv7fwlKhZeCEIN93bjNBdQl23aWHVuJCG3pVMGHpMqXES1WodohkTRKmiitbhj2cwKfsKoR8S2Xem7hgn6iBKt4zS8lSfZC8lD1gkNaoLykGa-Y5odYN2KjtwyU3gxw1yHbN_phZgj9qGAeuKy7Rn5MufzZP7-ImPNiz8lHX3-MlCFyVXfXztxZyMx4dtqWt-By5VGv3Na0fHrsqjrhU4BkKVuvrVOPlKl9tU9IIN6aCjD0HvX5QWUIUNM3taXoyNYJfrZD9Zv72KyYzUoShdD8Yst9Fxt4IBrvxvPeA-zWWCzDxvd6lRxzUuhxKLDXzoqYFm6ewJ5X_Wr-Mi7Y-1i9Log0dr0t5rcxfmxZ6lnsgfKSJK2LHp5S3HKO0rsfZDSSJQsdZdL8Fsqn-rBgRmT1i7duf3IPxiJMTt07ZcmOWYBqvsKFcnW--spFeZX57yAg3njScETCm7iFBK-onax38iSC4m_4kJEEe1ySMPK4RfOe4B4qSoVG6EZRJn0ulG-ZWdcKjpL53K76MfQVXYKW8JF_sQdOkuyMS_wcnesT0UfpFnxavk0vgjgbqbkmu91J83Gfdr1py4zpm4FTFeCvppqwOz-7KyPIAqjj8Lb1wNmcHvKumjDso92bt7Jl0iOlafcru1e9cZtupZz_zysYrTrmb-SzRkHrv4diUtbLnuT19nlt59Q7HYifoSRgGNOhZ1CjXZpBomAUwDq2h05iPf4rT1A9TBYOpofCou7dynAbHT-_pm02EHWMdqJsSB-Uv5zfyx7T7IbqJoyK8aceOiG7leVZOpLAblO3L2kGQc1t2_3M3ez5Za1Uf8SWYFHPa5ImpLlVjf-0F4ivuWCWNeysWgXbOZz_gS-9uOhZ3P9Gg-F62CnlLurmov4w_D-IpiHhJCmb758hIS2YmrO4AzvUXiJe96l0jJg6i8vfs89lj5O5rTArY7Ft75mLgGqQcISA9fgatfATHwXjCm5hDkdOv4Llq__-QlmhQLsCgZ_Sk3IOKWFAxi0yzagEKrg17qJBx2nmoR2b2DTbArbASJnn9Iay1hJMMcbpT0huSkGr_uNaJTb1UfXYzOXyh2h4EXeBNGe6RmZdBmkjIW4mT-GLxBPOrxHRVINoUU8dL_ZdRy1w5XdJvzIVqPg4pPYB94sEo_4FzaPaTQX9Fbw8i2qRYqE1Pbhef85fIAiZhdd7dMU9Zte8y1Gfh8NHY0S5OzCdoUEw9-yJ5ynSLnqZ0uy6s2Ovf-MtcRwuIBi8tLxLCVW2rAORzmFJ3O6rTZygCA-XAl69Sijbqb-ugNKdcTVanrxgWeNXQQYUx-S9-zZeu5uMo3PHqPsptKlybA2MGXcktLUonvmcEYhWZVD8Zh6NODQfo3ucRy7_4vTw6xula42ivTgmEYcIaMglbfknmyF5WYhtjNKK36xl8d_X6tQJvRM0ZyiTxPrc-FLAj2v-5N643zlqGNb4Ky30eO0Xyrm5GeKbsEk6I9HIXcSt" rel="nofollow" target="_blank">SABS</a>), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company that is developing human anti-thymocyte immunoglobulin (ATG) http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Highlights+Data+in+Multiple+Presentations+at+EASD/25353500.html Fri, 19 Sep 2025 07:24:00 -0500 A.09642568 O.20371933 O.49911890 SABS SABSW SAB BIO Highlights Data in Multiple Presentations at EASD http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Highlights+Data+in+Multiple+Presentations+at+EASD/25353500.html <p align="center"><em>-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in the study-</em></p> <p align="center"><em>-Data in multiple SAB presentations and INNODIA’s MELD-ATG study provide further validation for SAB-142 as a novel, potentially best-in-class, disease-modifying immunotherapeutic approach poised to redefine treatment of T1D- </em></p> <p>MIAMI, Sept. 19, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=t-7hR8Sbe-uz6ZhkF4YYNucl6WbqnQlpRFIg9iyK6_rRtb6UTj5-QNej20Ws50cT-1FWmxwEMd__zZzVaho9VupTCZoKnzVTuY4iTAQqCpwAdXVnSmsrAccw2DglgZGTvOSnJG-uNkVkt5nAvUB3KwUwid1XC0QjbMfDPWdQuQ6yBEazTv8k5y8KSUZaKQduYcazVWMiPkAnX20bphcUulQoxUlZMOL9FcqdOou0mDR0uMTOcnSuRXfvWyLLvZDsdPFJnPo1aw2SSsQE54Cw8dxE0ieuE2SjrCOxZEqyW-OyMZ2QaCuBoyhgFnduMEZkUIRvw69AsZp1epuSOzqmv3a6v1oZhi24Za0LxWBfzp-ugneGOWlelzoGgCo_WtgIqOW0K0bLcDIRQ6wmnmy0JhXK9o5EHuqTGOK9EG5F_gAv4PNQUqU3d9fGXnoNBjHs57LNB9Pw3TJuhI_cVY9cdGw-3NxHi0aj04RYfwCEBRZnlgZMUDm3XTZf87HBzsetyEAQj_u_IT2ZGYWrS_lTzmAEwMbR3YKrfYcN7IutU_5g6O-y4hxkbhwZyIhn86T8ARSrzB1AKPfrwqhG6OSDp6N3t2r1kgDSB4Q4AdzRcHv7fwlKhZeCEIN93bjNBdQl23aWHVuJCG3pVMGHpMqXES1WodohkTRKmiitbhj2cwKfsKoR8S2Xem7hgn6iBKt4zS8lSfZC8lD1gkNaoLykGa-Y5odYN2KjtwyU3gxw1yHbN_phZgj9qGAeuKy7Rn5MufzZP7-ImPNiz8lHX3-MlCFyVXfXztxZyMx4dtqWt-By5VGv3Na0fHrsqjrhU4BkKVuvrVOPlKl9tU9IIN6aCjD0HvX5QWUIUNM3taXoyNYJfrZD9Zv72KyYzUoShdD8Yst9Fxt4IBrvxvPeA-zWWCzDxvd6lRxzUuhxKLDXzoqYFm6ewJ5X_Wr-Mi7Y-1i9Log0dr0t5rcxfmxZ6lnsgfKSJK2LHp5S3HKO0rsfZDSSJQsdZdL8Fsqn-rBgRmT1i7duf3IPxiJMTt07ZcmOWYBqvsKFcnW--spFeZX57yAg3njScETCm7iFBK-onax38iSC4m_4kJEEe1ySMPK4RfOe4B4qSoVG6EZRJn0ulG-ZWdcKjpL53K76MfQVXYKW8JF_sQdOkuyMS_wcnesT0UfpFnxavk0vgjgbqbkmu91J83Gfdr1py4zpm4FTFeCvppqwOz-7KyPIAqjj8Lb1wNmcHvKumjDso92bt7Jl0iOlafcru1e9cZtupZz_zysYrTrmb-SzRkHrv4diUtbLnuT19nlt59Q7HYifoSRgGNOhZ1CjXZpBomAUwDq2h05iPf4rT1A9TBYOpofCou7dynAbHT-_pm02EHWMdqJsSB-Uv5zfyx7T7IbqJoyK8aceOiG7leVZOpLAblO3L2kGQc1t2_3M3ez5Za1Uf8SWYFHPa5ImpLlVjf-0F4ivuWCWNeysWgXbOZz_gS-9uOhZ3P9Gg-F62CnlLurmov4w_D-IpiHhJCmb758hIS2YmrO4AzvUXiJe96l0jJg6i8vfs89lj5O5rTArY7Ft75mLgGqQcISA9fgatfATHwXjCm5hDkdOv4Llq__-QlmhQLsCgZ_Sk3IOKWFAxi0yzagEKrg17qJBx2nmoR2b2DTbArbASJnn9Iay1hJMMcbpT0huSkGr_uNaJTb1UfXYzOXyh2h4EXeBNGe6RmZdBmkjIW4mT-GLxBPOrxHRVINoUU8dL_ZdRy1w5XdJvzIVqPg4pPYB94sEo_4FzaPaTQX9Fbw8i2qRYqE1Pbhef85fIAiZhdd7dMU9Zte8y1Gfh8NHY0S5OzCdoUEw9-yJ5ynSLnqZ0uy6s2Ovf-MtcRwuIBi8tLxLCVW2rAORzmFJ3O6rTZygCA-XAl69Sijbqb-ugNKdcTVanrxgWeNXQQYUx-S9-zZeu5uMo3PHqPsptKlybA2MGXcktLUonvmcEYhWZVD8Zh6NODQfo3ucRy7_4vTw6xula42ivTgmEYcIaMglbfknmyF5WYhtjNKK36xl8d_X6tQJvRM0ZyiTxPrc-FLAj2v-5N643zlqGNb4Ky30eO0Xyrm5GeKbsEk6I9HIXcSt" rel="nofollow" target="_blank">SABS</a>), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company that is developing human anti-thymocyte immunoglobulin (ATG) http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Highlights+Data+in+Multiple+Presentations+at+EASD/25353500.html Fri, 19 Sep 2025 07:24:00 -0500 A.09642568 O.20371933 O.49911890 SABS SABSW SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates http://www.streetinsider.com/Press+Releases/SAB+BIO+Announces+Q1+2025+Financial+Results+and+Provides+Company+Updates/24770380.html <p align="left">MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ElgDrGExLe6uuZGVnboKyDEAZHNfZ8W692qesTc0aBgr9yllzZqzIpP_RWig5atCFdMYR_r9h-PV7-1r8Gdl-paqQDj6cLm7WFiYXxivETXNNwuDjP79iack7yiy27qDx2F92N_DbrIRWqnhxU3HK0tsJQv738V1JFEWxOGKxUZFJKm0rkagKz45UgFdXejl4pFKokxgCwykSTa3rICRHNVgNj5gKxVpDCfYbx2C_ZfkkSI2JGloqL4c_KGB33ejCy3ToE8MjfkcJYY9TQw-k7w6wVWdpdTYI9jZK6de07u6Xkls8DN2Ctt_Z40EIjexmsMs5IiYHrd_aWN-mdS1Y752n1jlbOim4yRRbJSnrn3iLewX5UnRCrY-RFUTPSMd8BiF4XF5pzCvtAtZwMPH-SkI8XkSDbSq8TdyXs11rZjDSOjVuvsNBNMwVNh31KcR9odCyt0MvKCzmeC-a5T1rl4mt3mCaVx0Oqj2KJkxbAqsz6_XAyXnwqnDbEG3s9CFbxw7yK47SsOc4CqHnJjfAcmboWETFU5Fo0Su7cBwPoyA9TD5I1UyjkaEPZeUr1C1zdk_W_SUst9QZF4KMHP1DMKiDLT0ZGnMtt_Eqaed5gLcVoOuI0dnNsbWm9O9u9aiSOuPfFu1aNu4q8GvDsDKlp2HOohd8Ciu7_4I4UmZwLaNJLmbvo6Jw7JAQNePhbFxdFWL7DSQLoqDFsXBdgTjjAN6ZjR2YB6kqnhVIf8mkICiv-2WS9_KVXiZmfbtmLRFAFIIQNkkpyWG1fvZPrdV2cJ4g6M6vDtql6rAkKC10tbbT0tSTc0HOYZW-JV5EV843i8irG3GJeYGwOOizy44Z5GacHZ9MY_hAluuIFStMPsQomfHGpA4IyTsbDDwLkwdos30toJ8in-qI6Egx116AGnAKMEF7aRigOliwIuKZDZkxyIkqaDfMu74WABkvVehXYh8beHkYeo2ZWw-YKR5iaMXXC2oDMNZG4ijvPjgyxUxVmhmvZJpES6zkvIVb5wcTCbcLrtpssge8zPWwxRabMf8qpYmgmUZkoel_u-zG9Js7NzwtpCrPDVk58kYUHpeZzNPyF377AMBPAb0gWtoNGX8XeXAftXaFQlKCvgoLsLITehQSrpoUMTQMxg2UzRKDfr1AVCP0Y4WnvNmBss61MqXnMGidznVE5VYMpTbGO40qI2a8Smg0zvlb-194u_XgAbttsvYVo04Cj1fJFp8HPWmScaCmfB4ORMFi82K-nerl8JRtZ02W22sOqHmthd40HRU8hMGAs2BFqckt3nv3UPsseVmP4ibPm82vtHfW3vSBOlwZ93PhdauczYd66YJg8XL7vk2iMHo97lsBDM0MXnu81A0MXRTEcYZsZ2Xcfe0ljOaTWsCSgvVeRW5erhKyeWcQx14uXBtLDroL4Yx0HhSvTxQ4Ega6nAgODR96F-Ch3qOu6JE5Q9TCTw-KtgoPKpqXsLknG9WOvoBiqs02rZVx8ZvXODqGoqmdEMtUHQOzIS3iUE-AzLjGbrpUlQcCZ96SfP7ApE5qr9zVpPDbpKQ5OV35IcycxiajX4xMMvrtptlybpY6zvT6nA_YycOaPVwviHZUhGz4gthSlqMkXOdHulWz-MEkWHpyOIMdzejEtQ0nTEB2GYtlE9R4vC_gSF1BS93PCgpmk_sMZCFE83snRlIEZal8WDJB1D8Y_Gn0YYlHenCJIWxnmgQC6HND2CaBqTlpDgKoMJb8uJ86gSxBih7w5ghfee5XtPuls89fiXbbwXy5XVF0RbRPsNbywL6gOkM_ERagAvQIOAM-7P7Xg9tmQhmJq_XZtOKibKrKXOK3QMGHijJGHFb-NRrkVnL9ul3jYVHtKxu0OFPZsl99WiizSLyfH9AjZAJYsYItynHJy12uI8XE9Q0n7cORzpTG_5A13RKLCfBwaBk9FqlF50-yW4Wu2WPwvscu4vU2fdxplkeZpy0LVAE2HqULCsEuqqZ2cZn3YMGwHlU1XUVM2AdXEzzFevJUEO1ljLe_HjXYTnxzLec6KmB5FegCqG96PGVScMyCWkxHwOh9yi07dkAwygMrrC0RADmvZZmBhtb5OazOn_2XGvUUqYt" rel="nofollow" target="_blank">SABS</a>), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced financial results for the quarter ending March 31, 2025, and reported on recent developments.</p> <p>Samuel J. Reich, Chairman and CEO of SAB BIO, stated, “We have made strong progress this quarter on our corporate strategy and mission to deliver a transformational therapy that can halt or http://www.streetinsider.com/Press+Releases/SAB+BIO+Announces+Q1+2025+Financial+Results+and+Provides+Company+Updates/24770380.html Fri, 09 May 2025 09:00:00 -0500 A.09642568 O.20371933 O.49911890 SABS SABSW SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates http://www.streetinsider.com/Press+Releases/SAB+BIO+Announces+Q1+2025+Financial+Results+and+Provides+Company+Updates/24770380.html <p align="left">MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ElgDrGExLe6uuZGVnboKyDEAZHNfZ8W692qesTc0aBgr9yllzZqzIpP_RWig5atCFdMYR_r9h-PV7-1r8Gdl-paqQDj6cLm7WFiYXxivETXNNwuDjP79iack7yiy27qDx2F92N_DbrIRWqnhxU3HK0tsJQv738V1JFEWxOGKxUZFJKm0rkagKz45UgFdXejl4pFKokxgCwykSTa3rICRHNVgNj5gKxVpDCfYbx2C_ZfkkSI2JGloqL4c_KGB33ejCy3ToE8MjfkcJYY9TQw-k7w6wVWdpdTYI9jZK6de07u6Xkls8DN2Ctt_Z40EIjexmsMs5IiYHrd_aWN-mdS1Y752n1jlbOim4yRRbJSnrn3iLewX5UnRCrY-RFUTPSMd8BiF4XF5pzCvtAtZwMPH-SkI8XkSDbSq8TdyXs11rZjDSOjVuvsNBNMwVNh31KcR9odCyt0MvKCzmeC-a5T1rl4mt3mCaVx0Oqj2KJkxbAqsz6_XAyXnwqnDbEG3s9CFbxw7yK47SsOc4CqHnJjfAcmboWETFU5Fo0Su7cBwPoyA9TD5I1UyjkaEPZeUr1C1zdk_W_SUst9QZF4KMHP1DMKiDLT0ZGnMtt_Eqaed5gLcVoOuI0dnNsbWm9O9u9aiSOuPfFu1aNu4q8GvDsDKlp2HOohd8Ciu7_4I4UmZwLaNJLmbvo6Jw7JAQNePhbFxdFWL7DSQLoqDFsXBdgTjjAN6ZjR2YB6kqnhVIf8mkICiv-2WS9_KVXiZmfbtmLRFAFIIQNkkpyWG1fvZPrdV2cJ4g6M6vDtql6rAkKC10tbbT0tSTc0HOYZW-JV5EV843i8irG3GJeYGwOOizy44Z5GacHZ9MY_hAluuIFStMPsQomfHGpA4IyTsbDDwLkwdos30toJ8in-qI6Egx116AGnAKMEF7aRigOliwIuKZDZkxyIkqaDfMu74WABkvVehXYh8beHkYeo2ZWw-YKR5iaMXXC2oDMNZG4ijvPjgyxUxVmhmvZJpES6zkvIVb5wcTCbcLrtpssge8zPWwxRabMf8qpYmgmUZkoel_u-zG9Js7NzwtpCrPDVk58kYUHpeZzNPyF377AMBPAb0gWtoNGX8XeXAftXaFQlKCvgoLsLITehQSrpoUMTQMxg2UzRKDfr1AVCP0Y4WnvNmBss61MqXnMGidznVE5VYMpTbGO40qI2a8Smg0zvlb-194u_XgAbttsvYVo04Cj1fJFp8HPWmScaCmfB4ORMFi82K-nerl8JRtZ02W22sOqHmthd40HRU8hMGAs2BFqckt3nv3UPsseVmP4ibPm82vtHfW3vSBOlwZ93PhdauczYd66YJg8XL7vk2iMHo97lsBDM0MXnu81A0MXRTEcYZsZ2Xcfe0ljOaTWsCSgvVeRW5erhKyeWcQx14uXBtLDroL4Yx0HhSvTxQ4Ega6nAgODR96F-Ch3qOu6JE5Q9TCTw-KtgoPKpqXsLknG9WOvoBiqs02rZVx8ZvXODqGoqmdEMtUHQOzIS3iUE-AzLjGbrpUlQcCZ96SfP7ApE5qr9zVpPDbpKQ5OV35IcycxiajX4xMMvrtptlybpY6zvT6nA_YycOaPVwviHZUhGz4gthSlqMkXOdHulWz-MEkWHpyOIMdzejEtQ0nTEB2GYtlE9R4vC_gSF1BS93PCgpmk_sMZCFE83snRlIEZal8WDJB1D8Y_Gn0YYlHenCJIWxnmgQC6HND2CaBqTlpDgKoMJb8uJ86gSxBih7w5ghfee5XtPuls89fiXbbwXy5XVF0RbRPsNbywL6gOkM_ERagAvQIOAM-7P7Xg9tmQhmJq_XZtOKibKrKXOK3QMGHijJGHFb-NRrkVnL9ul3jYVHtKxu0OFPZsl99WiizSLyfH9AjZAJYsYItynHJy12uI8XE9Q0n7cORzpTG_5A13RKLCfBwaBk9FqlF50-yW4Wu2WPwvscu4vU2fdxplkeZpy0LVAE2HqULCsEuqqZ2cZn3YMGwHlU1XUVM2AdXEzzFevJUEO1ljLe_HjXYTnxzLec6KmB5FegCqG96PGVScMyCWkxHwOh9yi07dkAwygMrrC0RADmvZZmBhtb5OazOn_2XGvUUqYt" rel="nofollow" target="_blank">SABS</a>), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced financial results for the quarter ending March 31, 2025, and reported on recent developments.</p> <p>Samuel J. Reich, Chairman and CEO of SAB BIO, stated, “We have made strong progress this quarter on our corporate strategy and mission to deliver a transformational therapy that can halt or http://www.streetinsider.com/Press+Releases/SAB+BIO+Announces+Q1+2025+Financial+Results+and+Provides+Company+Updates/24770380.html Fri, 09 May 2025 09:00:00 -0500 A.09642568 O.20371933 O.49911890 SABS SABSW SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates http://www.streetinsider.com/Press+Releases/SAB+BIO+Announces+Q1+2025+Financial+Results+and+Provides+Company+Updates/24770380.html <p align="left">MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ElgDrGExLe6uuZGVnboKyDEAZHNfZ8W692qesTc0aBgr9yllzZqzIpP_RWig5atCFdMYR_r9h-PV7-1r8Gdl-paqQDj6cLm7WFiYXxivETXNNwuDjP79iack7yiy27qDx2F92N_DbrIRWqnhxU3HK0tsJQv738V1JFEWxOGKxUZFJKm0rkagKz45UgFdXejl4pFKokxgCwykSTa3rICRHNVgNj5gKxVpDCfYbx2C_ZfkkSI2JGloqL4c_KGB33ejCy3ToE8MjfkcJYY9TQw-k7w6wVWdpdTYI9jZK6de07u6Xkls8DN2Ctt_Z40EIjexmsMs5IiYHrd_aWN-mdS1Y752n1jlbOim4yRRbJSnrn3iLewX5UnRCrY-RFUTPSMd8BiF4XF5pzCvtAtZwMPH-SkI8XkSDbSq8TdyXs11rZjDSOjVuvsNBNMwVNh31KcR9odCyt0MvKCzmeC-a5T1rl4mt3mCaVx0Oqj2KJkxbAqsz6_XAyXnwqnDbEG3s9CFbxw7yK47SsOc4CqHnJjfAcmboWETFU5Fo0Su7cBwPoyA9TD5I1UyjkaEPZeUr1C1zdk_W_SUst9QZF4KMHP1DMKiDLT0ZGnMtt_Eqaed5gLcVoOuI0dnNsbWm9O9u9aiSOuPfFu1aNu4q8GvDsDKlp2HOohd8Ciu7_4I4UmZwLaNJLmbvo6Jw7JAQNePhbFxdFWL7DSQLoqDFsXBdgTjjAN6ZjR2YB6kqnhVIf8mkICiv-2WS9_KVXiZmfbtmLRFAFIIQNkkpyWG1fvZPrdV2cJ4g6M6vDtql6rAkKC10tbbT0tSTc0HOYZW-JV5EV843i8irG3GJeYGwOOizy44Z5GacHZ9MY_hAluuIFStMPsQomfHGpA4IyTsbDDwLkwdos30toJ8in-qI6Egx116AGnAKMEF7aRigOliwIuKZDZkxyIkqaDfMu74WABkvVehXYh8beHkYeo2ZWw-YKR5iaMXXC2oDMNZG4ijvPjgyxUxVmhmvZJpES6zkvIVb5wcTCbcLrtpssge8zPWwxRabMf8qpYmgmUZkoel_u-zG9Js7NzwtpCrPDVk58kYUHpeZzNPyF377AMBPAb0gWtoNGX8XeXAftXaFQlKCvgoLsLITehQSrpoUMTQMxg2UzRKDfr1AVCP0Y4WnvNmBss61MqXnMGidznVE5VYMpTbGO40qI2a8Smg0zvlb-194u_XgAbttsvYVo04Cj1fJFp8HPWmScaCmfB4ORMFi82K-nerl8JRtZ02W22sOqHmthd40HRU8hMGAs2BFqckt3nv3UPsseVmP4ibPm82vtHfW3vSBOlwZ93PhdauczYd66YJg8XL7vk2iMHo97lsBDM0MXnu81A0MXRTEcYZsZ2Xcfe0ljOaTWsCSgvVeRW5erhKyeWcQx14uXBtLDroL4Yx0HhSvTxQ4Ega6nAgODR96F-Ch3qOu6JE5Q9TCTw-KtgoPKpqXsLknG9WOvoBiqs02rZVx8ZvXODqGoqmdEMtUHQOzIS3iUE-AzLjGbrpUlQcCZ96SfP7ApE5qr9zVpPDbpKQ5OV35IcycxiajX4xMMvrtptlybpY6zvT6nA_YycOaPVwviHZUhGz4gthSlqMkXOdHulWz-MEkWHpyOIMdzejEtQ0nTEB2GYtlE9R4vC_gSF1BS93PCgpmk_sMZCFE83snRlIEZal8WDJB1D8Y_Gn0YYlHenCJIWxnmgQC6HND2CaBqTlpDgKoMJb8uJ86gSxBih7w5ghfee5XtPuls89fiXbbwXy5XVF0RbRPsNbywL6gOkM_ERagAvQIOAM-7P7Xg9tmQhmJq_XZtOKibKrKXOK3QMGHijJGHFb-NRrkVnL9ul3jYVHtKxu0OFPZsl99WiizSLyfH9AjZAJYsYItynHJy12uI8XE9Q0n7cORzpTG_5A13RKLCfBwaBk9FqlF50-yW4Wu2WPwvscu4vU2fdxplkeZpy0LVAE2HqULCsEuqqZ2cZn3YMGwHlU1XUVM2AdXEzzFevJUEO1ljLe_HjXYTnxzLec6KmB5FegCqG96PGVScMyCWkxHwOh9yi07dkAwygMrrC0RADmvZZmBhtb5OazOn_2XGvUUqYt" rel="nofollow" target="_blank">SABS</a>), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced financial results for the quarter ending March 31, 2025, and reported on recent developments.</p> <p>Samuel J. Reich, Chairman and CEO of SAB BIO, stated, “We have made strong progress this quarter on our corporate strategy and mission to deliver a transformational therapy that can halt or http://www.streetinsider.com/Press+Releases/SAB+BIO+Announces+Q1+2025+Financial+Results+and+Provides+Company+Updates/24770380.html Fri, 09 May 2025 09:00:00 -0500 A.09642568 O.20371933 O.49911890 SABS SABSW SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates http://www.streetinsider.com/Press+Releases/SAB+BIO+Announces+Q1+2025+Financial+Results+and+Provides+Company+Updates/24770380.html <p align="left">MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ElgDrGExLe6uuZGVnboKyDEAZHNfZ8W692qesTc0aBgr9yllzZqzIpP_RWig5atCFdMYR_r9h-PV7-1r8Gdl-paqQDj6cLm7WFiYXxivETXNNwuDjP79iack7yiy27qDx2F92N_DbrIRWqnhxU3HK0tsJQv738V1JFEWxOGKxUZFJKm0rkagKz45UgFdXejl4pFKokxgCwykSTa3rICRHNVgNj5gKxVpDCfYbx2C_ZfkkSI2JGloqL4c_KGB33ejCy3ToE8MjfkcJYY9TQw-k7w6wVWdpdTYI9jZK6de07u6Xkls8DN2Ctt_Z40EIjexmsMs5IiYHrd_aWN-mdS1Y752n1jlbOim4yRRbJSnrn3iLewX5UnRCrY-RFUTPSMd8BiF4XF5pzCvtAtZwMPH-SkI8XkSDbSq8TdyXs11rZjDSOjVuvsNBNMwVNh31KcR9odCyt0MvKCzmeC-a5T1rl4mt3mCaVx0Oqj2KJkxbAqsz6_XAyXnwqnDbEG3s9CFbxw7yK47SsOc4CqHnJjfAcmboWETFU5Fo0Su7cBwPoyA9TD5I1UyjkaEPZeUr1C1zdk_W_SUst9QZF4KMHP1DMKiDLT0ZGnMtt_Eqaed5gLcVoOuI0dnNsbWm9O9u9aiSOuPfFu1aNu4q8GvDsDKlp2HOohd8Ciu7_4I4UmZwLaNJLmbvo6Jw7JAQNePhbFxdFWL7DSQLoqDFsXBdgTjjAN6ZjR2YB6kqnhVIf8mkICiv-2WS9_KVXiZmfbtmLRFAFIIQNkkpyWG1fvZPrdV2cJ4g6M6vDtql6rAkKC10tbbT0tSTc0HOYZW-JV5EV843i8irG3GJeYGwOOizy44Z5GacHZ9MY_hAluuIFStMPsQomfHGpA4IyTsbDDwLkwdos30toJ8in-qI6Egx116AGnAKMEF7aRigOliwIuKZDZkxyIkqaDfMu74WABkvVehXYh8beHkYeo2ZWw-YKR5iaMXXC2oDMNZG4ijvPjgyxUxVmhmvZJpES6zkvIVb5wcTCbcLrtpssge8zPWwxRabMf8qpYmgmUZkoel_u-zG9Js7NzwtpCrPDVk58kYUHpeZzNPyF377AMBPAb0gWtoNGX8XeXAftXaFQlKCvgoLsLITehQSrpoUMTQMxg2UzRKDfr1AVCP0Y4WnvNmBss61MqXnMGidznVE5VYMpTbGO40qI2a8Smg0zvlb-194u_XgAbttsvYVo04Cj1fJFp8HPWmScaCmfB4ORMFi82K-nerl8JRtZ02W22sOqHmthd40HRU8hMGAs2BFqckt3nv3UPsseVmP4ibPm82vtHfW3vSBOlwZ93PhdauczYd66YJg8XL7vk2iMHo97lsBDM0MXnu81A0MXRTEcYZsZ2Xcfe0ljOaTWsCSgvVeRW5erhKyeWcQx14uXBtLDroL4Yx0HhSvTxQ4Ega6nAgODR96F-Ch3qOu6JE5Q9TCTw-KtgoPKpqXsLknG9WOvoBiqs02rZVx8ZvXODqGoqmdEMtUHQOzIS3iUE-AzLjGbrpUlQcCZ96SfP7ApE5qr9zVpPDbpKQ5OV35IcycxiajX4xMMvrtptlybpY6zvT6nA_YycOaPVwviHZUhGz4gthSlqMkXOdHulWz-MEkWHpyOIMdzejEtQ0nTEB2GYtlE9R4vC_gSF1BS93PCgpmk_sMZCFE83snRlIEZal8WDJB1D8Y_Gn0YYlHenCJIWxnmgQC6HND2CaBqTlpDgKoMJb8uJ86gSxBih7w5ghfee5XtPuls89fiXbbwXy5XVF0RbRPsNbywL6gOkM_ERagAvQIOAM-7P7Xg9tmQhmJq_XZtOKibKrKXOK3QMGHijJGHFb-NRrkVnL9ul3jYVHtKxu0OFPZsl99WiizSLyfH9AjZAJYsYItynHJy12uI8XE9Q0n7cORzpTG_5A13RKLCfBwaBk9FqlF50-yW4Wu2WPwvscu4vU2fdxplkeZpy0LVAE2HqULCsEuqqZ2cZn3YMGwHlU1XUVM2AdXEzzFevJUEO1ljLe_HjXYTnxzLec6KmB5FegCqG96PGVScMyCWkxHwOh9yi07dkAwygMrrC0RADmvZZmBhtb5OazOn_2XGvUUqYt" rel="nofollow" target="_blank">SABS</a>), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced financial results for the quarter ending March 31, 2025, and reported on recent developments.</p> <p>Samuel J. Reich, Chairman and CEO of SAB BIO, stated, “We have made strong progress this quarter on our corporate strategy and mission to deliver a transformational therapy that can halt or http://www.streetinsider.com/Press+Releases/SAB+BIO+Announces+Q1+2025+Financial+Results+and+Provides+Company+Updates/24770380.html Fri, 09 May 2025 09:00:00 -0500 A.09642568 O.20371933 O.49911890 SABS SABSW SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates http://www.streetinsider.com/Press+Releases/SAB+BIO+Announces+Q1+2025+Financial+Results+and+Provides+Company+Updates/24770380.html <p align="left">MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ElgDrGExLe6uuZGVnboKyDEAZHNfZ8W692qesTc0aBgr9yllzZqzIpP_RWig5atCFdMYR_r9h-PV7-1r8Gdl-paqQDj6cLm7WFiYXxivETXNNwuDjP79iack7yiy27qDx2F92N_DbrIRWqnhxU3HK0tsJQv738V1JFEWxOGKxUZFJKm0rkagKz45UgFdXejl4pFKokxgCwykSTa3rICRHNVgNj5gKxVpDCfYbx2C_ZfkkSI2JGloqL4c_KGB33ejCy3ToE8MjfkcJYY9TQw-k7w6wVWdpdTYI9jZK6de07u6Xkls8DN2Ctt_Z40EIjexmsMs5IiYHrd_aWN-mdS1Y752n1jlbOim4yRRbJSnrn3iLewX5UnRCrY-RFUTPSMd8BiF4XF5pzCvtAtZwMPH-SkI8XkSDbSq8TdyXs11rZjDSOjVuvsNBNMwVNh31KcR9odCyt0MvKCzmeC-a5T1rl4mt3mCaVx0Oqj2KJkxbAqsz6_XAyXnwqnDbEG3s9CFbxw7yK47SsOc4CqHnJjfAcmboWETFU5Fo0Su7cBwPoyA9TD5I1UyjkaEPZeUr1C1zdk_W_SUst9QZF4KMHP1DMKiDLT0ZGnMtt_Eqaed5gLcVoOuI0dnNsbWm9O9u9aiSOuPfFu1aNu4q8GvDsDKlp2HOohd8Ciu7_4I4UmZwLaNJLmbvo6Jw7JAQNePhbFxdFWL7DSQLoqDFsXBdgTjjAN6ZjR2YB6kqnhVIf8mkICiv-2WS9_KVXiZmfbtmLRFAFIIQNkkpyWG1fvZPrdV2cJ4g6M6vDtql6rAkKC10tbbT0tSTc0HOYZW-JV5EV843i8irG3GJeYGwOOizy44Z5GacHZ9MY_hAluuIFStMPsQomfHGpA4IyTsbDDwLkwdos30toJ8in-qI6Egx116AGnAKMEF7aRigOliwIuKZDZkxyIkqaDfMu74WABkvVehXYh8beHkYeo2ZWw-YKR5iaMXXC2oDMNZG4ijvPjgyxUxVmhmvZJpES6zkvIVb5wcTCbcLrtpssge8zPWwxRabMf8qpYmgmUZkoel_u-zG9Js7NzwtpCrPDVk58kYUHpeZzNPyF377AMBPAb0gWtoNGX8XeXAftXaFQlKCvgoLsLITehQSrpoUMTQMxg2UzRKDfr1AVCP0Y4WnvNmBss61MqXnMGidznVE5VYMpTbGO40qI2a8Smg0zvlb-194u_XgAbttsvYVo04Cj1fJFp8HPWmScaCmfB4ORMFi82K-nerl8JRtZ02W22sOqHmthd40HRU8hMGAs2BFqckt3nv3UPsseVmP4ibPm82vtHfW3vSBOlwZ93PhdauczYd66YJg8XL7vk2iMHo97lsBDM0MXnu81A0MXRTEcYZsZ2Xcfe0ljOaTWsCSgvVeRW5erhKyeWcQx14uXBtLDroL4Yx0HhSvTxQ4Ega6nAgODR96F-Ch3qOu6JE5Q9TCTw-KtgoPKpqXsLknG9WOvoBiqs02rZVx8ZvXODqGoqmdEMtUHQOzIS3iUE-AzLjGbrpUlQcCZ96SfP7ApE5qr9zVpPDbpKQ5OV35IcycxiajX4xMMvrtptlybpY6zvT6nA_YycOaPVwviHZUhGz4gthSlqMkXOdHulWz-MEkWHpyOIMdzejEtQ0nTEB2GYtlE9R4vC_gSF1BS93PCgpmk_sMZCFE83snRlIEZal8WDJB1D8Y_Gn0YYlHenCJIWxnmgQC6HND2CaBqTlpDgKoMJb8uJ86gSxBih7w5ghfee5XtPuls89fiXbbwXy5XVF0RbRPsNbywL6gOkM_ERagAvQIOAM-7P7Xg9tmQhmJq_XZtOKibKrKXOK3QMGHijJGHFb-NRrkVnL9ul3jYVHtKxu0OFPZsl99WiizSLyfH9AjZAJYsYItynHJy12uI8XE9Q0n7cORzpTG_5A13RKLCfBwaBk9FqlF50-yW4Wu2WPwvscu4vU2fdxplkeZpy0LVAE2HqULCsEuqqZ2cZn3YMGwHlU1XUVM2AdXEzzFevJUEO1ljLe_HjXYTnxzLec6KmB5FegCqG96PGVScMyCWkxHwOh9yi07dkAwygMrrC0RADmvZZmBhtb5OazOn_2XGvUUqYt" rel="nofollow" target="_blank">SABS</a>), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced financial results for the quarter ending March 31, 2025, and reported on recent developments.</p> <p>Samuel J. Reich, Chairman and CEO of SAB BIO, stated, “We have made strong progress this quarter on our corporate strategy and mission to deliver a transformational therapy that can halt or http://www.streetinsider.com/Press+Releases/SAB+BIO+Announces+Q1+2025+Financial+Results+and+Provides+Company+Updates/24770380.html Fri, 09 May 2025 09:00:00 -0500 A.09642568 O.20371933 O.49911890 SABS SABSW SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Announces+Q1+2025+Financial+Results+and+Provides+Company+Updates/24770380.html <p align="left">MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ElgDrGExLe6uuZGVnboKyDEAZHNfZ8W692qesTc0aBgr9yllzZqzIpP_RWig5atCFdMYR_r9h-PV7-1r8Gdl-paqQDj6cLm7WFiYXxivETXNNwuDjP79iack7yiy27qDx2F92N_DbrIRWqnhxU3HK0tsJQv738V1JFEWxOGKxUZFJKm0rkagKz45UgFdXejl4pFKokxgCwykSTa3rICRHNVgNj5gKxVpDCfYbx2C_ZfkkSI2JGloqL4c_KGB33ejCy3ToE8MjfkcJYY9TQw-k7w6wVWdpdTYI9jZK6de07u6Xkls8DN2Ctt_Z40EIjexmsMs5IiYHrd_aWN-mdS1Y752n1jlbOim4yRRbJSnrn3iLewX5UnRCrY-RFUTPSMd8BiF4XF5pzCvtAtZwMPH-SkI8XkSDbSq8TdyXs11rZjDSOjVuvsNBNMwVNh31KcR9odCyt0MvKCzmeC-a5T1rl4mt3mCaVx0Oqj2KJkxbAqsz6_XAyXnwqnDbEG3s9CFbxw7yK47SsOc4CqHnJjfAcmboWETFU5Fo0Su7cBwPoyA9TD5I1UyjkaEPZeUr1C1zdk_W_SUst9QZF4KMHP1DMKiDLT0ZGnMtt_Eqaed5gLcVoOuI0dnNsbWm9O9u9aiSOuPfFu1aNu4q8GvDsDKlp2HOohd8Ciu7_4I4UmZwLaNJLmbvo6Jw7JAQNePhbFxdFWL7DSQLoqDFsXBdgTjjAN6ZjR2YB6kqnhVIf8mkICiv-2WS9_KVXiZmfbtmLRFAFIIQNkkpyWG1fvZPrdV2cJ4g6M6vDtql6rAkKC10tbbT0tSTc0HOYZW-JV5EV843i8irG3GJeYGwOOizy44Z5GacHZ9MY_hAluuIFStMPsQomfHGpA4IyTsbDDwLkwdos30toJ8in-qI6Egx116AGnAKMEF7aRigOliwIuKZDZkxyIkqaDfMu74WABkvVehXYh8beHkYeo2ZWw-YKR5iaMXXC2oDMNZG4ijvPjgyxUxVmhmvZJpES6zkvIVb5wcTCbcLrtpssge8zPWwxRabMf8qpYmgmUZkoel_u-zG9Js7NzwtpCrPDVk58kYUHpeZzNPyF377AMBPAb0gWtoNGX8XeXAftXaFQlKCvgoLsLITehQSrpoUMTQMxg2UzRKDfr1AVCP0Y4WnvNmBss61MqXnMGidznVE5VYMpTbGO40qI2a8Smg0zvlb-194u_XgAbttsvYVo04Cj1fJFp8HPWmScaCmfB4ORMFi82K-nerl8JRtZ02W22sOqHmthd40HRU8hMGAs2BFqckt3nv3UPsseVmP4ibPm82vtHfW3vSBOlwZ93PhdauczYd66YJg8XL7vk2iMHo97lsBDM0MXnu81A0MXRTEcYZsZ2Xcfe0ljOaTWsCSgvVeRW5erhKyeWcQx14uXBtLDroL4Yx0HhSvTxQ4Ega6nAgODR96F-Ch3qOu6JE5Q9TCTw-KtgoPKpqXsLknG9WOvoBiqs02rZVx8ZvXODqGoqmdEMtUHQOzIS3iUE-AzLjGbrpUlQcCZ96SfP7ApE5qr9zVpPDbpKQ5OV35IcycxiajX4xMMvrtptlybpY6zvT6nA_YycOaPVwviHZUhGz4gthSlqMkXOdHulWz-MEkWHpyOIMdzejEtQ0nTEB2GYtlE9R4vC_gSF1BS93PCgpmk_sMZCFE83snRlIEZal8WDJB1D8Y_Gn0YYlHenCJIWxnmgQC6HND2CaBqTlpDgKoMJb8uJ86gSxBih7w5ghfee5XtPuls89fiXbbwXy5XVF0RbRPsNbywL6gOkM_ERagAvQIOAM-7P7Xg9tmQhmJq_XZtOKibKrKXOK3QMGHijJGHFb-NRrkVnL9ul3jYVHtKxu0OFPZsl99WiizSLyfH9AjZAJYsYItynHJy12uI8XE9Q0n7cORzpTG_5A13RKLCfBwaBk9FqlF50-yW4Wu2WPwvscu4vU2fdxplkeZpy0LVAE2HqULCsEuqqZ2cZn3YMGwHlU1XUVM2AdXEzzFevJUEO1ljLe_HjXYTnxzLec6KmB5FegCqG96PGVScMyCWkxHwOh9yi07dkAwygMrrC0RADmvZZmBhtb5OazOn_2XGvUUqYt" rel="nofollow" target="_blank">SABS</a>), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced financial results for the quarter ending March 31, 2025, and reported on recent developments.</p> <p>Samuel J. Reich, Chairman and CEO of SAB BIO, stated, “We have made strong progress this quarter on our corporate strategy and mission to deliver a transformational therapy that can halt or http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Announces+Q1+2025+Financial+Results+and+Provides+Company+Updates/24770380.html Fri, 09 May 2025 09:00:00 -0500 A.09642568 O.20371933 O.49911890 SABS SABSW SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Announces+Q1+2025+Financial+Results+and+Provides+Company+Updates/24770380.html <p align="left">MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ElgDrGExLe6uuZGVnboKyDEAZHNfZ8W692qesTc0aBgr9yllzZqzIpP_RWig5atCFdMYR_r9h-PV7-1r8Gdl-paqQDj6cLm7WFiYXxivETXNNwuDjP79iack7yiy27qDx2F92N_DbrIRWqnhxU3HK0tsJQv738V1JFEWxOGKxUZFJKm0rkagKz45UgFdXejl4pFKokxgCwykSTa3rICRHNVgNj5gKxVpDCfYbx2C_ZfkkSI2JGloqL4c_KGB33ejCy3ToE8MjfkcJYY9TQw-k7w6wVWdpdTYI9jZK6de07u6Xkls8DN2Ctt_Z40EIjexmsMs5IiYHrd_aWN-mdS1Y752n1jlbOim4yRRbJSnrn3iLewX5UnRCrY-RFUTPSMd8BiF4XF5pzCvtAtZwMPH-SkI8XkSDbSq8TdyXs11rZjDSOjVuvsNBNMwVNh31KcR9odCyt0MvKCzmeC-a5T1rl4mt3mCaVx0Oqj2KJkxbAqsz6_XAyXnwqnDbEG3s9CFbxw7yK47SsOc4CqHnJjfAcmboWETFU5Fo0Su7cBwPoyA9TD5I1UyjkaEPZeUr1C1zdk_W_SUst9QZF4KMHP1DMKiDLT0ZGnMtt_Eqaed5gLcVoOuI0dnNsbWm9O9u9aiSOuPfFu1aNu4q8GvDsDKlp2HOohd8Ciu7_4I4UmZwLaNJLmbvo6Jw7JAQNePhbFxdFWL7DSQLoqDFsXBdgTjjAN6ZjR2YB6kqnhVIf8mkICiv-2WS9_KVXiZmfbtmLRFAFIIQNkkpyWG1fvZPrdV2cJ4g6M6vDtql6rAkKC10tbbT0tSTc0HOYZW-JV5EV843i8irG3GJeYGwOOizy44Z5GacHZ9MY_hAluuIFStMPsQomfHGpA4IyTsbDDwLkwdos30toJ8in-qI6Egx116AGnAKMEF7aRigOliwIuKZDZkxyIkqaDfMu74WABkvVehXYh8beHkYeo2ZWw-YKR5iaMXXC2oDMNZG4ijvPjgyxUxVmhmvZJpES6zkvIVb5wcTCbcLrtpssge8zPWwxRabMf8qpYmgmUZkoel_u-zG9Js7NzwtpCrPDVk58kYUHpeZzNPyF377AMBPAb0gWtoNGX8XeXAftXaFQlKCvgoLsLITehQSrpoUMTQMxg2UzRKDfr1AVCP0Y4WnvNmBss61MqXnMGidznVE5VYMpTbGO40qI2a8Smg0zvlb-194u_XgAbttsvYVo04Cj1fJFp8HPWmScaCmfB4ORMFi82K-nerl8JRtZ02W22sOqHmthd40HRU8hMGAs2BFqckt3nv3UPsseVmP4ibPm82vtHfW3vSBOlwZ93PhdauczYd66YJg8XL7vk2iMHo97lsBDM0MXnu81A0MXRTEcYZsZ2Xcfe0ljOaTWsCSgvVeRW5erhKyeWcQx14uXBtLDroL4Yx0HhSvTxQ4Ega6nAgODR96F-Ch3qOu6JE5Q9TCTw-KtgoPKpqXsLknG9WOvoBiqs02rZVx8ZvXODqGoqmdEMtUHQOzIS3iUE-AzLjGbrpUlQcCZ96SfP7ApE5qr9zVpPDbpKQ5OV35IcycxiajX4xMMvrtptlybpY6zvT6nA_YycOaPVwviHZUhGz4gthSlqMkXOdHulWz-MEkWHpyOIMdzejEtQ0nTEB2GYtlE9R4vC_gSF1BS93PCgpmk_sMZCFE83snRlIEZal8WDJB1D8Y_Gn0YYlHenCJIWxnmgQC6HND2CaBqTlpDgKoMJb8uJ86gSxBih7w5ghfee5XtPuls89fiXbbwXy5XVF0RbRPsNbywL6gOkM_ERagAvQIOAM-7P7Xg9tmQhmJq_XZtOKibKrKXOK3QMGHijJGHFb-NRrkVnL9ul3jYVHtKxu0OFPZsl99WiizSLyfH9AjZAJYsYItynHJy12uI8XE9Q0n7cORzpTG_5A13RKLCfBwaBk9FqlF50-yW4Wu2WPwvscu4vU2fdxplkeZpy0LVAE2HqULCsEuqqZ2cZn3YMGwHlU1XUVM2AdXEzzFevJUEO1ljLe_HjXYTnxzLec6KmB5FegCqG96PGVScMyCWkxHwOh9yi07dkAwygMrrC0RADmvZZmBhtb5OazOn_2XGvUUqYt" rel="nofollow" target="_blank">SABS</a>), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced financial results for the quarter ending March 31, 2025, and reported on recent developments.</p> <p>Samuel J. Reich, Chairman and CEO of SAB BIO, stated, “We have made strong progress this quarter on our corporate strategy and mission to deliver a transformational therapy that can halt or http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Announces+Q1+2025+Financial+Results+and+Provides+Company+Updates/24770380.html Fri, 09 May 2025 09:00:00 -0500 A.09642568 O.20371933 O.49911890 SABS SABSW SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Announces+Q1+2025+Financial+Results+and+Provides+Company+Updates/24770380.html <p align="left">MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ElgDrGExLe6uuZGVnboKyDEAZHNfZ8W692qesTc0aBgr9yllzZqzIpP_RWig5atCFdMYR_r9h-PV7-1r8Gdl-paqQDj6cLm7WFiYXxivETXNNwuDjP79iack7yiy27qDx2F92N_DbrIRWqnhxU3HK0tsJQv738V1JFEWxOGKxUZFJKm0rkagKz45UgFdXejl4pFKokxgCwykSTa3rICRHNVgNj5gKxVpDCfYbx2C_ZfkkSI2JGloqL4c_KGB33ejCy3ToE8MjfkcJYY9TQw-k7w6wVWdpdTYI9jZK6de07u6Xkls8DN2Ctt_Z40EIjexmsMs5IiYHrd_aWN-mdS1Y752n1jlbOim4yRRbJSnrn3iLewX5UnRCrY-RFUTPSMd8BiF4XF5pzCvtAtZwMPH-SkI8XkSDbSq8TdyXs11rZjDSOjVuvsNBNMwVNh31KcR9odCyt0MvKCzmeC-a5T1rl4mt3mCaVx0Oqj2KJkxbAqsz6_XAyXnwqnDbEG3s9CFbxw7yK47SsOc4CqHnJjfAcmboWETFU5Fo0Su7cBwPoyA9TD5I1UyjkaEPZeUr1C1zdk_W_SUst9QZF4KMHP1DMKiDLT0ZGnMtt_Eqaed5gLcVoOuI0dnNsbWm9O9u9aiSOuPfFu1aNu4q8GvDsDKlp2HOohd8Ciu7_4I4UmZwLaNJLmbvo6Jw7JAQNePhbFxdFWL7DSQLoqDFsXBdgTjjAN6ZjR2YB6kqnhVIf8mkICiv-2WS9_KVXiZmfbtmLRFAFIIQNkkpyWG1fvZPrdV2cJ4g6M6vDtql6rAkKC10tbbT0tSTc0HOYZW-JV5EV843i8irG3GJeYGwOOizy44Z5GacHZ9MY_hAluuIFStMPsQomfHGpA4IyTsbDDwLkwdos30toJ8in-qI6Egx116AGnAKMEF7aRigOliwIuKZDZkxyIkqaDfMu74WABkvVehXYh8beHkYeo2ZWw-YKR5iaMXXC2oDMNZG4ijvPjgyxUxVmhmvZJpES6zkvIVb5wcTCbcLrtpssge8zPWwxRabMf8qpYmgmUZkoel_u-zG9Js7NzwtpCrPDVk58kYUHpeZzNPyF377AMBPAb0gWtoNGX8XeXAftXaFQlKCvgoLsLITehQSrpoUMTQMxg2UzRKDfr1AVCP0Y4WnvNmBss61MqXnMGidznVE5VYMpTbGO40qI2a8Smg0zvlb-194u_XgAbttsvYVo04Cj1fJFp8HPWmScaCmfB4ORMFi82K-nerl8JRtZ02W22sOqHmthd40HRU8hMGAs2BFqckt3nv3UPsseVmP4ibPm82vtHfW3vSBOlwZ93PhdauczYd66YJg8XL7vk2iMHo97lsBDM0MXnu81A0MXRTEcYZsZ2Xcfe0ljOaTWsCSgvVeRW5erhKyeWcQx14uXBtLDroL4Yx0HhSvTxQ4Ega6nAgODR96F-Ch3qOu6JE5Q9TCTw-KtgoPKpqXsLknG9WOvoBiqs02rZVx8ZvXODqGoqmdEMtUHQOzIS3iUE-AzLjGbrpUlQcCZ96SfP7ApE5qr9zVpPDbpKQ5OV35IcycxiajX4xMMvrtptlybpY6zvT6nA_YycOaPVwviHZUhGz4gthSlqMkXOdHulWz-MEkWHpyOIMdzejEtQ0nTEB2GYtlE9R4vC_gSF1BS93PCgpmk_sMZCFE83snRlIEZal8WDJB1D8Y_Gn0YYlHenCJIWxnmgQC6HND2CaBqTlpDgKoMJb8uJ86gSxBih7w5ghfee5XtPuls89fiXbbwXy5XVF0RbRPsNbywL6gOkM_ERagAvQIOAM-7P7Xg9tmQhmJq_XZtOKibKrKXOK3QMGHijJGHFb-NRrkVnL9ul3jYVHtKxu0OFPZsl99WiizSLyfH9AjZAJYsYItynHJy12uI8XE9Q0n7cORzpTG_5A13RKLCfBwaBk9FqlF50-yW4Wu2WPwvscu4vU2fdxplkeZpy0LVAE2HqULCsEuqqZ2cZn3YMGwHlU1XUVM2AdXEzzFevJUEO1ljLe_HjXYTnxzLec6KmB5FegCqG96PGVScMyCWkxHwOh9yi07dkAwygMrrC0RADmvZZmBhtb5OazOn_2XGvUUqYt" rel="nofollow" target="_blank">SABS</a>), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced financial results for the quarter ending March 31, 2025, and reported on recent developments.</p> <p>Samuel J. Reich, Chairman and CEO of SAB BIO, stated, “We have made strong progress this quarter on our corporate strategy and mission to deliver a transformational therapy that can halt or http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Announces+Q1+2025+Financial+Results+and+Provides+Company+Updates/24770380.html Fri, 09 May 2025 09:00:00 -0500 A.09642568 O.20371933 O.49911890 SABS SABSW SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Announces+Q1+2025+Financial+Results+and+Provides+Company+Updates/24770380.html <p align="left">MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ElgDrGExLe6uuZGVnboKyDEAZHNfZ8W692qesTc0aBgr9yllzZqzIpP_RWig5atCFdMYR_r9h-PV7-1r8Gdl-paqQDj6cLm7WFiYXxivETXNNwuDjP79iack7yiy27qDx2F92N_DbrIRWqnhxU3HK0tsJQv738V1JFEWxOGKxUZFJKm0rkagKz45UgFdXejl4pFKokxgCwykSTa3rICRHNVgNj5gKxVpDCfYbx2C_ZfkkSI2JGloqL4c_KGB33ejCy3ToE8MjfkcJYY9TQw-k7w6wVWdpdTYI9jZK6de07u6Xkls8DN2Ctt_Z40EIjexmsMs5IiYHrd_aWN-mdS1Y752n1jlbOim4yRRbJSnrn3iLewX5UnRCrY-RFUTPSMd8BiF4XF5pzCvtAtZwMPH-SkI8XkSDbSq8TdyXs11rZjDSOjVuvsNBNMwVNh31KcR9odCyt0MvKCzmeC-a5T1rl4mt3mCaVx0Oqj2KJkxbAqsz6_XAyXnwqnDbEG3s9CFbxw7yK47SsOc4CqHnJjfAcmboWETFU5Fo0Su7cBwPoyA9TD5I1UyjkaEPZeUr1C1zdk_W_SUst9QZF4KMHP1DMKiDLT0ZGnMtt_Eqaed5gLcVoOuI0dnNsbWm9O9u9aiSOuPfFu1aNu4q8GvDsDKlp2HOohd8Ciu7_4I4UmZwLaNJLmbvo6Jw7JAQNePhbFxdFWL7DSQLoqDFsXBdgTjjAN6ZjR2YB6kqnhVIf8mkICiv-2WS9_KVXiZmfbtmLRFAFIIQNkkpyWG1fvZPrdV2cJ4g6M6vDtql6rAkKC10tbbT0tSTc0HOYZW-JV5EV843i8irG3GJeYGwOOizy44Z5GacHZ9MY_hAluuIFStMPsQomfHGpA4IyTsbDDwLkwdos30toJ8in-qI6Egx116AGnAKMEF7aRigOliwIuKZDZkxyIkqaDfMu74WABkvVehXYh8beHkYeo2ZWw-YKR5iaMXXC2oDMNZG4ijvPjgyxUxVmhmvZJpES6zkvIVb5wcTCbcLrtpssge8zPWwxRabMf8qpYmgmUZkoel_u-zG9Js7NzwtpCrPDVk58kYUHpeZzNPyF377AMBPAb0gWtoNGX8XeXAftXaFQlKCvgoLsLITehQSrpoUMTQMxg2UzRKDfr1AVCP0Y4WnvNmBss61MqXnMGidznVE5VYMpTbGO40qI2a8Smg0zvlb-194u_XgAbttsvYVo04Cj1fJFp8HPWmScaCmfB4ORMFi82K-nerl8JRtZ02W22sOqHmthd40HRU8hMGAs2BFqckt3nv3UPsseVmP4ibPm82vtHfW3vSBOlwZ93PhdauczYd66YJg8XL7vk2iMHo97lsBDM0MXnu81A0MXRTEcYZsZ2Xcfe0ljOaTWsCSgvVeRW5erhKyeWcQx14uXBtLDroL4Yx0HhSvTxQ4Ega6nAgODR96F-Ch3qOu6JE5Q9TCTw-KtgoPKpqXsLknG9WOvoBiqs02rZVx8ZvXODqGoqmdEMtUHQOzIS3iUE-AzLjGbrpUlQcCZ96SfP7ApE5qr9zVpPDbpKQ5OV35IcycxiajX4xMMvrtptlybpY6zvT6nA_YycOaPVwviHZUhGz4gthSlqMkXOdHulWz-MEkWHpyOIMdzejEtQ0nTEB2GYtlE9R4vC_gSF1BS93PCgpmk_sMZCFE83snRlIEZal8WDJB1D8Y_Gn0YYlHenCJIWxnmgQC6HND2CaBqTlpDgKoMJb8uJ86gSxBih7w5ghfee5XtPuls89fiXbbwXy5XVF0RbRPsNbywL6gOkM_ERagAvQIOAM-7P7Xg9tmQhmJq_XZtOKibKrKXOK3QMGHijJGHFb-NRrkVnL9ul3jYVHtKxu0OFPZsl99WiizSLyfH9AjZAJYsYItynHJy12uI8XE9Q0n7cORzpTG_5A13RKLCfBwaBk9FqlF50-yW4Wu2WPwvscu4vU2fdxplkeZpy0LVAE2HqULCsEuqqZ2cZn3YMGwHlU1XUVM2AdXEzzFevJUEO1ljLe_HjXYTnxzLec6KmB5FegCqG96PGVScMyCWkxHwOh9yi07dkAwygMrrC0RADmvZZmBhtb5OazOn_2XGvUUqYt" rel="nofollow" target="_blank">SABS</a>), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced financial results for the quarter ending March 31, 2025, and reported on recent developments.</p> <p>Samuel J. Reich, Chairman and CEO of SAB BIO, stated, “We have made strong progress this quarter on our corporate strategy and mission to deliver a transformational therapy that can halt or http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Announces+Q1+2025+Financial+Results+and+Provides+Company+Updates/24770380.html Fri, 09 May 2025 09:00:00 -0500 A.09642568 O.20371933 O.49911890 SABS SABSW SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Announces+Q1+2025+Financial+Results+and+Provides+Company+Updates/24770380.html <p align="left">MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ElgDrGExLe6uuZGVnboKyDEAZHNfZ8W692qesTc0aBgr9yllzZqzIpP_RWig5atCFdMYR_r9h-PV7-1r8Gdl-paqQDj6cLm7WFiYXxivETXNNwuDjP79iack7yiy27qDx2F92N_DbrIRWqnhxU3HK0tsJQv738V1JFEWxOGKxUZFJKm0rkagKz45UgFdXejl4pFKokxgCwykSTa3rICRHNVgNj5gKxVpDCfYbx2C_ZfkkSI2JGloqL4c_KGB33ejCy3ToE8MjfkcJYY9TQw-k7w6wVWdpdTYI9jZK6de07u6Xkls8DN2Ctt_Z40EIjexmsMs5IiYHrd_aWN-mdS1Y752n1jlbOim4yRRbJSnrn3iLewX5UnRCrY-RFUTPSMd8BiF4XF5pzCvtAtZwMPH-SkI8XkSDbSq8TdyXs11rZjDSOjVuvsNBNMwVNh31KcR9odCyt0MvKCzmeC-a5T1rl4mt3mCaVx0Oqj2KJkxbAqsz6_XAyXnwqnDbEG3s9CFbxw7yK47SsOc4CqHnJjfAcmboWETFU5Fo0Su7cBwPoyA9TD5I1UyjkaEPZeUr1C1zdk_W_SUst9QZF4KMHP1DMKiDLT0ZGnMtt_Eqaed5gLcVoOuI0dnNsbWm9O9u9aiSOuPfFu1aNu4q8GvDsDKlp2HOohd8Ciu7_4I4UmZwLaNJLmbvo6Jw7JAQNePhbFxdFWL7DSQLoqDFsXBdgTjjAN6ZjR2YB6kqnhVIf8mkICiv-2WS9_KVXiZmfbtmLRFAFIIQNkkpyWG1fvZPrdV2cJ4g6M6vDtql6rAkKC10tbbT0tSTc0HOYZW-JV5EV843i8irG3GJeYGwOOizy44Z5GacHZ9MY_hAluuIFStMPsQomfHGpA4IyTsbDDwLkwdos30toJ8in-qI6Egx116AGnAKMEF7aRigOliwIuKZDZkxyIkqaDfMu74WABkvVehXYh8beHkYeo2ZWw-YKR5iaMXXC2oDMNZG4ijvPjgyxUxVmhmvZJpES6zkvIVb5wcTCbcLrtpssge8zPWwxRabMf8qpYmgmUZkoel_u-zG9Js7NzwtpCrPDVk58kYUHpeZzNPyF377AMBPAb0gWtoNGX8XeXAftXaFQlKCvgoLsLITehQSrpoUMTQMxg2UzRKDfr1AVCP0Y4WnvNmBss61MqXnMGidznVE5VYMpTbGO40qI2a8Smg0zvlb-194u_XgAbttsvYVo04Cj1fJFp8HPWmScaCmfB4ORMFi82K-nerl8JRtZ02W22sOqHmthd40HRU8hMGAs2BFqckt3nv3UPsseVmP4ibPm82vtHfW3vSBOlwZ93PhdauczYd66YJg8XL7vk2iMHo97lsBDM0MXnu81A0MXRTEcYZsZ2Xcfe0ljOaTWsCSgvVeRW5erhKyeWcQx14uXBtLDroL4Yx0HhSvTxQ4Ega6nAgODR96F-Ch3qOu6JE5Q9TCTw-KtgoPKpqXsLknG9WOvoBiqs02rZVx8ZvXODqGoqmdEMtUHQOzIS3iUE-AzLjGbrpUlQcCZ96SfP7ApE5qr9zVpPDbpKQ5OV35IcycxiajX4xMMvrtptlybpY6zvT6nA_YycOaPVwviHZUhGz4gthSlqMkXOdHulWz-MEkWHpyOIMdzejEtQ0nTEB2GYtlE9R4vC_gSF1BS93PCgpmk_sMZCFE83snRlIEZal8WDJB1D8Y_Gn0YYlHenCJIWxnmgQC6HND2CaBqTlpDgKoMJb8uJ86gSxBih7w5ghfee5XtPuls89fiXbbwXy5XVF0RbRPsNbywL6gOkM_ERagAvQIOAM-7P7Xg9tmQhmJq_XZtOKibKrKXOK3QMGHijJGHFb-NRrkVnL9ul3jYVHtKxu0OFPZsl99WiizSLyfH9AjZAJYsYItynHJy12uI8XE9Q0n7cORzpTG_5A13RKLCfBwaBk9FqlF50-yW4Wu2WPwvscu4vU2fdxplkeZpy0LVAE2HqULCsEuqqZ2cZn3YMGwHlU1XUVM2AdXEzzFevJUEO1ljLe_HjXYTnxzLec6KmB5FegCqG96PGVScMyCWkxHwOh9yi07dkAwygMrrC0RADmvZZmBhtb5OazOn_2XGvUUqYt" rel="nofollow" target="_blank">SABS</a>), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced financial results for the quarter ending March 31, 2025, and reported on recent developments.</p> <p>Samuel J. Reich, Chairman and CEO of SAB BIO, stated, “We have made strong progress this quarter on our corporate strategy and mission to deliver a transformational therapy that can halt or http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Announces+Q1+2025+Financial+Results+and+Provides+Company+Updates/24770380.html Fri, 09 May 2025 09:00:00 -0500 A.09642568 O.20371933 O.49911890 SABS SABSW SAB BIO Announces R&amp;D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy http://www.streetinsider.com/Press+Releases/SAB+BIO+Announces+R%26amp%3BD+Webinar+Event+to+Review+Phase+1+Topline+Results+for+SAB-142%2C+a+Disease-Modifying+T1D+Therapy/24237623.html <p align="left">MIAMI, Jan. 23, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=mpKt-yqxJj-SRk9ws1jn5jUuxVv2YhWHtBUxlejLhMR-0DYxqFWeni8VCMECWjhfWAoIo9hHAMgg3HplW6N0Y3nzTtmnQg3FolwWpLT7szAB4ghNReUBO0iCtOUh9fGfFgsyhq8Ma7cMxIRSwj5mnCD5EhNIBpLVu07MO6hvi5hKwTXWTHERRU-OXBnv5fkkkoip0BAzrtLafwZJ2CLk9b-WDOtXk3FL9EhgzdI9OQMroL6ITbvttCp7BDVYPQqwoh1czNS0D3JENePmUN21ziJQ4Z-CFsgqRbkKpg4JkSr_upw7irakpIupy_SsiZo8xUhjytDCgFgAOBcnWrZRm-5t9nRF8nj2EBu9i25lzPs4c89-OL9vSLU09EbgRDyJQ2GSeMFC-UtO9w4H8lQ_VOHtCc412HGROOyc-rsHaB9QPXl4zlH1aX8X6TGuIlOv5JEY7sVqHs4brfdRoead-ZGO9AbCm39hnRLynhO7G9AAHl2wPkoeuhyQhRjjEvtrYIiO8A8hUZaUonMRSj2jS8A9M1f3YBt5H8g83Yzm_KMtFKDxRaKGqYBU-ZnHXc8hkT7Mh2V1JCGxbjbxtck8V2Q2yv1VVpCocDVGFS3f1LZhEC31VBkvw_q6P9_hMEOjs659M_9pwm8OtbGmThSzbxF325WEhrXoV-UotFId2M4OimmL26LSn68ILVfRG3E-Ni_VoU51pPpDREQELosL_ZO_HUvSF7Uzt3aHV1K38VkArI4Ojv5_hF3nwww76BE7qCm--KAFNuA6glZgodJInmHS4d8DwvULGQV6wjP1ccf7L6DtJdP9I4ftfIznky3GjoVpPbX3vPPrbhkjh08Gs_GSM7Pd2f7DwpoAHx4FMPI_Kx6ziGbprCzxFJOGOAeEaSlTcABXd_mXlQ-CriyZ0og89XSehhXzPaylcY9DMpgqpZSy8dv5DeyYxJO-63a-Kvpk9PCVi-_ke8iASLJZ_rccMEgWqk-KA4HkGlihB-RTuEwjLeumudgvDKzr23RoPEW-bzjWb6x4XOG5KyDpBtCGVXRMkr_5uww0ihLwCeh3ZszbB2Glybr3wQwrraSsL7udNZiatczyVmNGEygFa6pDqB4t3a58UYFOPry_EFZAL3c3ojtmmyGirwl8x3zv57b10WRfiGC3I-t_DvgQb7qpZOsOnyRQxJaZlvm-WV3PkPOhjjCjS81_Xzz_zdOwojogySDk2sSI22nxtzLpeDJQ1Tg4-UTYd9B5knZKSUkYNlxMynQEnyt15H0aUaIXRDVNvbVXx9mcjLLkYdTFafsFop4Ugl10xsgqMDE7OXfH0DNqngXKGkyEmKog6Kx8LDu8S4NxBUbZdFe2Z2MBZhWru-MhQ75UMH_uKe7Gm2wjFUJTZffVlJUxqPVRzjJ7C5-f-J_8JvT2JcWACYBK7-TkcDy8mgnBNbCrJ-b9XMJ3jiVzxn7KAw5kTm9VvuXwNzwu0Syy0E9AnkH9QNLXNA==" rel="nofollow" target="_blank">SABS</a>), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), announced today that the Company will host a Research and Development webinar on January 28, 2025 to discuss the topline data for Phase 1 clinical trial for its lead candidate, SAB-142. The webinar will feature presentations from SAB BIO’s management team and T1D Key Opinion Leader (KOL) Michael Haller, MD, the division http://www.streetinsider.com/Press+Releases/SAB+BIO+Announces+R%26amp%3BD+Webinar+Event+to+Review+Phase+1+Topline+Results+for+SAB-142%2C+a+Disease-Modifying+T1D+Therapy/24237623.html Thu, 23 Jan 2025 07:00:00 -0500 A.09642568 A.12763360 O.20319167 O.20371933 O.49911890 SABS SABSW SAB BIO Announces R&amp;D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy http://www.streetinsider.com/Press+Releases/SAB+BIO+Announces+R%26amp%3BD+Webinar+Event+to+Review+Phase+1+Topline+Results+for+SAB-142%2C+a+Disease-Modifying+T1D+Therapy/24237623.html <p align="left">MIAMI, Jan. 23, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=mpKt-yqxJj-SRk9ws1jn5jUuxVv2YhWHtBUxlejLhMR-0DYxqFWeni8VCMECWjhfWAoIo9hHAMgg3HplW6N0Y3nzTtmnQg3FolwWpLT7szAB4ghNReUBO0iCtOUh9fGfFgsyhq8Ma7cMxIRSwj5mnCD5EhNIBpLVu07MO6hvi5hKwTXWTHERRU-OXBnv5fkkkoip0BAzrtLafwZJ2CLk9b-WDOtXk3FL9EhgzdI9OQMroL6ITbvttCp7BDVYPQqwoh1czNS0D3JENePmUN21ziJQ4Z-CFsgqRbkKpg4JkSr_upw7irakpIupy_SsiZo8xUhjytDCgFgAOBcnWrZRm-5t9nRF8nj2EBu9i25lzPs4c89-OL9vSLU09EbgRDyJQ2GSeMFC-UtO9w4H8lQ_VOHtCc412HGROOyc-rsHaB9QPXl4zlH1aX8X6TGuIlOv5JEY7sVqHs4brfdRoead-ZGO9AbCm39hnRLynhO7G9AAHl2wPkoeuhyQhRjjEvtrYIiO8A8hUZaUonMRSj2jS8A9M1f3YBt5H8g83Yzm_KMtFKDxRaKGqYBU-ZnHXc8hkT7Mh2V1JCGxbjbxtck8V2Q2yv1VVpCocDVGFS3f1LZhEC31VBkvw_q6P9_hMEOjs659M_9pwm8OtbGmThSzbxF325WEhrXoV-UotFId2M4OimmL26LSn68ILVfRG3E-Ni_VoU51pPpDREQELosL_ZO_HUvSF7Uzt3aHV1K38VkArI4Ojv5_hF3nwww76BE7qCm--KAFNuA6glZgodJInmHS4d8DwvULGQV6wjP1ccf7L6DtJdP9I4ftfIznky3GjoVpPbX3vPPrbhkjh08Gs_GSM7Pd2f7DwpoAHx4FMPI_Kx6ziGbprCzxFJOGOAeEaSlTcABXd_mXlQ-CriyZ0og89XSehhXzPaylcY9DMpgqpZSy8dv5DeyYxJO-63a-Kvpk9PCVi-_ke8iASLJZ_rccMEgWqk-KA4HkGlihB-RTuEwjLeumudgvDKzr23RoPEW-bzjWb6x4XOG5KyDpBtCGVXRMkr_5uww0ihLwCeh3ZszbB2Glybr3wQwrraSsL7udNZiatczyVmNGEygFa6pDqB4t3a58UYFOPry_EFZAL3c3ojtmmyGirwl8x3zv57b10WRfiGC3I-t_DvgQb7qpZOsOnyRQxJaZlvm-WV3PkPOhjjCjS81_Xzz_zdOwojogySDk2sSI22nxtzLpeDJQ1Tg4-UTYd9B5knZKSUkYNlxMynQEnyt15H0aUaIXRDVNvbVXx9mcjLLkYdTFafsFop4Ugl10xsgqMDE7OXfH0DNqngXKGkyEmKog6Kx8LDu8S4NxBUbZdFe2Z2MBZhWru-MhQ75UMH_uKe7Gm2wjFUJTZffVlJUxqPVRzjJ7C5-f-J_8JvT2JcWACYBK7-TkcDy8mgnBNbCrJ-b9XMJ3jiVzxn7KAw5kTm9VvuXwNzwu0Syy0E9AnkH9QNLXNA==" rel="nofollow" target="_blank">SABS</a>), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), announced today that the Company will host a Research and Development webinar on January 28, 2025 to discuss the topline data for Phase 1 clinical trial for its lead candidate, SAB-142. The webinar will feature presentations from SAB BIO’s management team and T1D Key Opinion Leader (KOL) Michael Haller, MD, the division http://www.streetinsider.com/Press+Releases/SAB+BIO+Announces+R%26amp%3BD+Webinar+Event+to+Review+Phase+1+Topline+Results+for+SAB-142%2C+a+Disease-Modifying+T1D+Therapy/24237623.html Thu, 23 Jan 2025 07:00:00 -0500 A.09642568 A.12763360 O.20319167 O.20371933 O.49911890 SABS SABSW SAB BIO Announces R&amp;D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy http://www.streetinsider.com/Press+Releases/SAB+BIO+Announces+R%26amp%3BD+Webinar+Event+to+Review+Phase+1+Topline+Results+for+SAB-142%2C+a+Disease-Modifying+T1D+Therapy/24237623.html <p align="left">MIAMI, Jan. 23, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=mpKt-yqxJj-SRk9ws1jn5jUuxVv2YhWHtBUxlejLhMR-0DYxqFWeni8VCMECWjhfWAoIo9hHAMgg3HplW6N0Y3nzTtmnQg3FolwWpLT7szAB4ghNReUBO0iCtOUh9fGfFgsyhq8Ma7cMxIRSwj5mnCD5EhNIBpLVu07MO6hvi5hKwTXWTHERRU-OXBnv5fkkkoip0BAzrtLafwZJ2CLk9b-WDOtXk3FL9EhgzdI9OQMroL6ITbvttCp7BDVYPQqwoh1czNS0D3JENePmUN21ziJQ4Z-CFsgqRbkKpg4JkSr_upw7irakpIupy_SsiZo8xUhjytDCgFgAOBcnWrZRm-5t9nRF8nj2EBu9i25lzPs4c89-OL9vSLU09EbgRDyJQ2GSeMFC-UtO9w4H8lQ_VOHtCc412HGROOyc-rsHaB9QPXl4zlH1aX8X6TGuIlOv5JEY7sVqHs4brfdRoead-ZGO9AbCm39hnRLynhO7G9AAHl2wPkoeuhyQhRjjEvtrYIiO8A8hUZaUonMRSj2jS8A9M1f3YBt5H8g83Yzm_KMtFKDxRaKGqYBU-ZnHXc8hkT7Mh2V1JCGxbjbxtck8V2Q2yv1VVpCocDVGFS3f1LZhEC31VBkvw_q6P9_hMEOjs659M_9pwm8OtbGmThSzbxF325WEhrXoV-UotFId2M4OimmL26LSn68ILVfRG3E-Ni_VoU51pPpDREQELosL_ZO_HUvSF7Uzt3aHV1K38VkArI4Ojv5_hF3nwww76BE7qCm--KAFNuA6glZgodJInmHS4d8DwvULGQV6wjP1ccf7L6DtJdP9I4ftfIznky3GjoVpPbX3vPPrbhkjh08Gs_GSM7Pd2f7DwpoAHx4FMPI_Kx6ziGbprCzxFJOGOAeEaSlTcABXd_mXlQ-CriyZ0og89XSehhXzPaylcY9DMpgqpZSy8dv5DeyYxJO-63a-Kvpk9PCVi-_ke8iASLJZ_rccMEgWqk-KA4HkGlihB-RTuEwjLeumudgvDKzr23RoPEW-bzjWb6x4XOG5KyDpBtCGVXRMkr_5uww0ihLwCeh3ZszbB2Glybr3wQwrraSsL7udNZiatczyVmNGEygFa6pDqB4t3a58UYFOPry_EFZAL3c3ojtmmyGirwl8x3zv57b10WRfiGC3I-t_DvgQb7qpZOsOnyRQxJaZlvm-WV3PkPOhjjCjS81_Xzz_zdOwojogySDk2sSI22nxtzLpeDJQ1Tg4-UTYd9B5knZKSUkYNlxMynQEnyt15H0aUaIXRDVNvbVXx9mcjLLkYdTFafsFop4Ugl10xsgqMDE7OXfH0DNqngXKGkyEmKog6Kx8LDu8S4NxBUbZdFe2Z2MBZhWru-MhQ75UMH_uKe7Gm2wjFUJTZffVlJUxqPVRzjJ7C5-f-J_8JvT2JcWACYBK7-TkcDy8mgnBNbCrJ-b9XMJ3jiVzxn7KAw5kTm9VvuXwNzwu0Syy0E9AnkH9QNLXNA==" rel="nofollow" target="_blank">SABS</a>), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), announced today that the Company will host a Research and Development webinar on January 28, 2025 to discuss the topline data for Phase 1 clinical trial for its lead candidate, SAB-142. The webinar will feature presentations from SAB BIO’s management team and T1D Key Opinion Leader (KOL) Michael Haller, MD, the division http://www.streetinsider.com/Press+Releases/SAB+BIO+Announces+R%26amp%3BD+Webinar+Event+to+Review+Phase+1+Topline+Results+for+SAB-142%2C+a+Disease-Modifying+T1D+Therapy/24237623.html Thu, 23 Jan 2025 07:00:00 -0500 A.09642568 A.12763360 O.20319167 O.20371933 O.49911890 SABS SABSW SAB BIO Announces R&amp;D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy http://www.streetinsider.com/Press+Releases/SAB+BIO+Announces+R%26amp%3BD+Webinar+Event+to+Review+Phase+1+Topline+Results+for+SAB-142%2C+a+Disease-Modifying+T1D+Therapy/24237623.html <p align="left">MIAMI, Jan. 23, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=mpKt-yqxJj-SRk9ws1jn5jUuxVv2YhWHtBUxlejLhMR-0DYxqFWeni8VCMECWjhfWAoIo9hHAMgg3HplW6N0Y3nzTtmnQg3FolwWpLT7szAB4ghNReUBO0iCtOUh9fGfFgsyhq8Ma7cMxIRSwj5mnCD5EhNIBpLVu07MO6hvi5hKwTXWTHERRU-OXBnv5fkkkoip0BAzrtLafwZJ2CLk9b-WDOtXk3FL9EhgzdI9OQMroL6ITbvttCp7BDVYPQqwoh1czNS0D3JENePmUN21ziJQ4Z-CFsgqRbkKpg4JkSr_upw7irakpIupy_SsiZo8xUhjytDCgFgAOBcnWrZRm-5t9nRF8nj2EBu9i25lzPs4c89-OL9vSLU09EbgRDyJQ2GSeMFC-UtO9w4H8lQ_VOHtCc412HGROOyc-rsHaB9QPXl4zlH1aX8X6TGuIlOv5JEY7sVqHs4brfdRoead-ZGO9AbCm39hnRLynhO7G9AAHl2wPkoeuhyQhRjjEvtrYIiO8A8hUZaUonMRSj2jS8A9M1f3YBt5H8g83Yzm_KMtFKDxRaKGqYBU-ZnHXc8hkT7Mh2V1JCGxbjbxtck8V2Q2yv1VVpCocDVGFS3f1LZhEC31VBkvw_q6P9_hMEOjs659M_9pwm8OtbGmThSzbxF325WEhrXoV-UotFId2M4OimmL26LSn68ILVfRG3E-Ni_VoU51pPpDREQELosL_ZO_HUvSF7Uzt3aHV1K38VkArI4Ojv5_hF3nwww76BE7qCm--KAFNuA6glZgodJInmHS4d8DwvULGQV6wjP1ccf7L6DtJdP9I4ftfIznky3GjoVpPbX3vPPrbhkjh08Gs_GSM7Pd2f7DwpoAHx4FMPI_Kx6ziGbprCzxFJOGOAeEaSlTcABXd_mXlQ-CriyZ0og89XSehhXzPaylcY9DMpgqpZSy8dv5DeyYxJO-63a-Kvpk9PCVi-_ke8iASLJZ_rccMEgWqk-KA4HkGlihB-RTuEwjLeumudgvDKzr23RoPEW-bzjWb6x4XOG5KyDpBtCGVXRMkr_5uww0ihLwCeh3ZszbB2Glybr3wQwrraSsL7udNZiatczyVmNGEygFa6pDqB4t3a58UYFOPry_EFZAL3c3ojtmmyGirwl8x3zv57b10WRfiGC3I-t_DvgQb7qpZOsOnyRQxJaZlvm-WV3PkPOhjjCjS81_Xzz_zdOwojogySDk2sSI22nxtzLpeDJQ1Tg4-UTYd9B5knZKSUkYNlxMynQEnyt15H0aUaIXRDVNvbVXx9mcjLLkYdTFafsFop4Ugl10xsgqMDE7OXfH0DNqngXKGkyEmKog6Kx8LDu8S4NxBUbZdFe2Z2MBZhWru-MhQ75UMH_uKe7Gm2wjFUJTZffVlJUxqPVRzjJ7C5-f-J_8JvT2JcWACYBK7-TkcDy8mgnBNbCrJ-b9XMJ3jiVzxn7KAw5kTm9VvuXwNzwu0Syy0E9AnkH9QNLXNA==" rel="nofollow" target="_blank">SABS</a>), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), announced today that the Company will host a Research and Development webinar on January 28, 2025 to discuss the topline data for Phase 1 clinical trial for its lead candidate, SAB-142. The webinar will feature presentations from SAB BIO’s management team and T1D Key Opinion Leader (KOL) Michael Haller, MD, the division http://www.streetinsider.com/Press+Releases/SAB+BIO+Announces+R%26amp%3BD+Webinar+Event+to+Review+Phase+1+Topline+Results+for+SAB-142%2C+a+Disease-Modifying+T1D+Therapy/24237623.html Thu, 23 Jan 2025 07:00:00 -0500 A.09642568 A.12763360 O.20319167 O.20371933 O.49911890 SABS SABSW SAB BIO Announces R&amp;D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy http://www.streetinsider.com/Press+Releases/SAB+BIO+Announces+R%26amp%3BD+Webinar+Event+to+Review+Phase+1+Topline+Results+for+SAB-142%2C+a+Disease-Modifying+T1D+Therapy/24237623.html <p align="left">MIAMI, Jan. 23, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=mpKt-yqxJj-SRk9ws1jn5jUuxVv2YhWHtBUxlejLhMR-0DYxqFWeni8VCMECWjhfWAoIo9hHAMgg3HplW6N0Y3nzTtmnQg3FolwWpLT7szAB4ghNReUBO0iCtOUh9fGfFgsyhq8Ma7cMxIRSwj5mnCD5EhNIBpLVu07MO6hvi5hKwTXWTHERRU-OXBnv5fkkkoip0BAzrtLafwZJ2CLk9b-WDOtXk3FL9EhgzdI9OQMroL6ITbvttCp7BDVYPQqwoh1czNS0D3JENePmUN21ziJQ4Z-CFsgqRbkKpg4JkSr_upw7irakpIupy_SsiZo8xUhjytDCgFgAOBcnWrZRm-5t9nRF8nj2EBu9i25lzPs4c89-OL9vSLU09EbgRDyJQ2GSeMFC-UtO9w4H8lQ_VOHtCc412HGROOyc-rsHaB9QPXl4zlH1aX8X6TGuIlOv5JEY7sVqHs4brfdRoead-ZGO9AbCm39hnRLynhO7G9AAHl2wPkoeuhyQhRjjEvtrYIiO8A8hUZaUonMRSj2jS8A9M1f3YBt5H8g83Yzm_KMtFKDxRaKGqYBU-ZnHXc8hkT7Mh2V1JCGxbjbxtck8V2Q2yv1VVpCocDVGFS3f1LZhEC31VBkvw_q6P9_hMEOjs659M_9pwm8OtbGmThSzbxF325WEhrXoV-UotFId2M4OimmL26LSn68ILVfRG3E-Ni_VoU51pPpDREQELosL_ZO_HUvSF7Uzt3aHV1K38VkArI4Ojv5_hF3nwww76BE7qCm--KAFNuA6glZgodJInmHS4d8DwvULGQV6wjP1ccf7L6DtJdP9I4ftfIznky3GjoVpPbX3vPPrbhkjh08Gs_GSM7Pd2f7DwpoAHx4FMPI_Kx6ziGbprCzxFJOGOAeEaSlTcABXd_mXlQ-CriyZ0og89XSehhXzPaylcY9DMpgqpZSy8dv5DeyYxJO-63a-Kvpk9PCVi-_ke8iASLJZ_rccMEgWqk-KA4HkGlihB-RTuEwjLeumudgvDKzr23RoPEW-bzjWb6x4XOG5KyDpBtCGVXRMkr_5uww0ihLwCeh3ZszbB2Glybr3wQwrraSsL7udNZiatczyVmNGEygFa6pDqB4t3a58UYFOPry_EFZAL3c3ojtmmyGirwl8x3zv57b10WRfiGC3I-t_DvgQb7qpZOsOnyRQxJaZlvm-WV3PkPOhjjCjS81_Xzz_zdOwojogySDk2sSI22nxtzLpeDJQ1Tg4-UTYd9B5knZKSUkYNlxMynQEnyt15H0aUaIXRDVNvbVXx9mcjLLkYdTFafsFop4Ugl10xsgqMDE7OXfH0DNqngXKGkyEmKog6Kx8LDu8S4NxBUbZdFe2Z2MBZhWru-MhQ75UMH_uKe7Gm2wjFUJTZffVlJUxqPVRzjJ7C5-f-J_8JvT2JcWACYBK7-TkcDy8mgnBNbCrJ-b9XMJ3jiVzxn7KAw5kTm9VvuXwNzwu0Syy0E9AnkH9QNLXNA==" rel="nofollow" target="_blank">SABS</a>), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), announced today that the Company will host a Research and Development webinar on January 28, 2025 to discuss the topline data for Phase 1 clinical trial for its lead candidate, SAB-142. The webinar will feature presentations from SAB BIO’s management team and T1D Key Opinion Leader (KOL) Michael Haller, MD, the division http://www.streetinsider.com/Press+Releases/SAB+BIO+Announces+R%26amp%3BD+Webinar+Event+to+Review+Phase+1+Topline+Results+for+SAB-142%2C+a+Disease-Modifying+T1D+Therapy/24237623.html Thu, 23 Jan 2025 07:00:00 -0500 A.09642568 A.12763360 O.20319167 O.20371933 O.49911890 SABS SABSW